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In 1992 the “Institut für Bioanorganische und Radiopharmazeutische Chemie” (Institute of Bioinorganic 
and Radiopharmaceutical Chemistry) was founded as one of the scientific units within the For-
schungszentrum Rossendorf e. V. (Research Centre Rossendorf). Prof. Dr. Johannsen, who was the 
director until 2003, established the Institute and developed its scientific and organisational profile.   
From 2003 to 2005, during a challenging time of evaluation and major changes of the central admini-
stration, Dr. Spies and Prof. Dr. van den Hoff accepted the responsibility of leading the Institute 
through the transitional phase. Since October 1st 2005 the Institute has a new director, Prof. Dr. Jörg 
Steinbach.  
 
The organisation of the Institute was adjusted to the Institute’s tasks. There are three departments 
working together:  
- Department of Radiopharmaceutical Chemistry 
- Department of Radiopharmaceutical Biology 
- Department of Positron Emission Tomography 
The first two departments are further structured according to their specialisation. 
 
After years of successful work, on the 1st of January 2006, the name of the Institute was changed from 
“Institut für Bioanorganische und Radiopharmazeutische Chemie” to ‘”Institut für Radiopharmazie” 
(Institute of Radiopharmacy). This is due to the changed characteristics of the scientific content. 
Whereas during the first years the chemical disciplines dominated the scientific approach, nowadays, 
biosciences have more influence on the scientific content. Taking this fact into account, the corre-
sponding staffs of the Department of Radiopharmaceutical Biology was enlarged. Together with the 
Department of Radiopharmaceutical Chemistry, including the group for production of radiopharmaceu-
ticals, and the medical and medical-physics oriented Department of Positron Emission Tomography 
(working in close connection with the Clinic of Nuclear Medicine of the Medical Faculty of the Techni-
cal University of Dresden) the Institute covers a broad spectrum of radiopharmaceutical disciplines. 
The adaptation of its name to suit the modern structure is the consequence.  
 
The general scientific task remains similar: the development and application of radiotracers for visuali-
sation and quantification of functional processes as well as the application of radionuclides for thera-
peutic purposes. The scientific activities will be further focused on radiopharmaceutical cancer re-
search. Diagnostic as well as therapeutical questions will be investigated in a close collaboration with 
the Centre for Innovation Competence (OncoRay, radiotherapy). Overlapping investigations to meta-
bolic research complete the general program.  
The close coordination of the programmes of both, the Institute of Radiopharmacy, Research Centre 
Rossendorf and the Department of Radiopharmacy, Institute of Interdisciplinary Isotope Research, 
Leipzig within the “Radiopharmazieverbund Sachsen” (Saxonian Radiopharmaceutical Network) gives 
the chance to direct scientific questions to the most experienced site: the scientific activities in cancer 
research of the Rossendorf institute are complemented by the Leipzig institute, which focuses on ra-
diopharmaceutical neuroscientific research. 
 
On the basis of the tasks mentioned above and the new structure, the Institute of Radiopharmacy will 
continue its basic and application-oriented efforts for high-quality scientific research in the future. An 
important prerequisite is the close cooperation with various national and international institutions and 
companies. This is an already successfully ongoing process which has to be continued.  
The high qualified and experienced, permanent and temporary staff of the Institute will guarantee for 
the success of further work.  
 
The contributions of the Annual Report are already published in various scientific journals or deal with 
improvement of important techniques. This is different to the previous reports. 
 
The members of the Institute wish to acknowledge the ongoing support of general funding by the Free 
State of Saxony and the Federal Government.  
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11C-C Bond Formation by Palladium-Mediated Cross-Coupling of 
Alkenylzircocenes with [11C]Methyl Iodide 
M. Berndt, F. Wüst 
 
The hydrozirconation of internal alkynes, followed by transmetallation with Pd(PPh )3 4 and subsequent cross-
coupling with [11C]methyl iodide to give several 11C-labelled α,α’-dimethyl substituted alkenes is described. 
 
Introduction 
11A synthetic strategy to form C-labelled α,α’-
dimethyl substituted alkenes includes forma-
tion of alkenylzirconocenes by the syn-in-
sertion of a C-C triple bond into the Zr-H bond 
of Schwartz reagent [Cp2ZrHCl] followed by 
transition metal-mediated 11C-C bond forma-







   [11C]MeI
M(PPh3)4










Fig. 1. Transmetallation of alkenylzirconocenes and 
subsequent cross-coupling with [11C]methyl iodide. 
 
Addition of one equivalent Schwartz reagent 
onto unsymmetrically substituted internal al-
kynes may lead to a mixture of regioisomers 2 
and 2’ enriched in the regioisomer where the 
zirconium-carbon bond is placed geminal to 
the sterically less demanding substituent [1]. 
However, further treatment with Schwartz re-
agent readily isomerises the mixture of regioi-
somers presumably via a dimetallated inter-
mediate to favour the formation of the thermo-
dynamically stable isomer 2. 
The reaction conditions were optimised by the 
conversion of prop-1-ynyl-benzene 1a using 
several group 10 transition metal complexes 
[2]. Transition metal complexes Ni(PPh3)4 or 
Pt(PPh3)4 gave only 4 % and 11 % radio-
chemical yield, respectively, whereas sufficient 
radiochemical yields of up to 70 % could be 
obtained when Pd(PPh3)4 was used. 
 
Results and Discussion 
To elaborate the scope and limitations of the 
novel radiolabelling method, optimised reaction 
conditions were applied to the radiosynthesis 
of other 11C-labelled alkenes bearing a prenyl 
group. The results are summarised in Table 1. 
In contrast to the hydrozirconation reaction 
employing model compound 1a, a total amount 
of 2.5 equivalents of Schwartz reagent was 
used in the case of sterically less hindered 
internal alkynes 1b, 1c, 1d, 1e and 1g to force 
the hydrozirconation reaction in favour to 
thermodynamically controlled regioselectivity 
as described in Fig. 1. 
 
Table 1. Radiochemical yield (RCY) determined by ana-
lytical radio-HPLC referring to as the percentage of the 
total amount of radioactivity in the reaction mixture. 
R Equiv. Cp
[11C]CH I RCY 3
ZrClH [%] [%] 2
Ph (1a) 1.2 30 70 (3a) 
Ph-O-CH2 (1b) 2.5 35 65 (3b) 
C (1c) (CH3)3 2.5 25 75 (3c) 
 (1d) CH3CH2CH2 2.5 50 50 (3d) 
 (1e) TBDMSO-CH2 2.5 30 70 (3e) 
 (1f) OH-CH2 5.0 38 62 (3f) 
 (1g) 5 (3g) (4-NO2-C H )-O-CH 2.5 95 6 4 2
 (1h) Ph-CO2-CH2 1.2 >95 - (3h) 
 
Subsequent transmetallation with Pd(PPh3)4 
and treatment with [11C]methyl iodide gave the 
desired cross-coupled products [11C]3b, 
[11C]3c, [11C]3d and [11C]3e in good radio-
chemical yields. The obtained low radiochemi-
cal yield (5 %) of 4-nitrophenyl compound 
[11C]3g is an example for the incompatibility of 
Schwartz reagent towards nitro groups. Radio-
synthesis of ester [11C]3h completely failed 
due to undesired side reactions of Schwartz 
reagent with the ester group. In the case of 
butynol 1f a larger excess of 5.0 equivalents of 
Schwartz reagent had to be used to compen-
sate the reaction of Schwartz reagent with the 
free OH-group. In summary we have elabo-
rated a novel 11C-C bond forming reaction 
based upon the palladium-mediated cross-
coupling between alkenylzirconocenes with 
[11C]methyl iodide. The excellent regioselectiv-
ity of the formed alkenyl-zirconocene com-
plexes makes this approach a promising route 
for the convenient preparation of 11C-labelled 
compounds containing a prenyl group. How-
ever, easily reducible functional groups such 
as nitro groups or esters are not compatible 
with the reaction conditions employing 
Schwartz reagent for the hydrozirconation 
reaction of internal alkynes. 
 
Published in: Berndt, M., Wuest, F., J. Labelled Compd. 
Radiopharm. 49 (2006) 91-100. 
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Synthesis of [11C]CH OTf by Different Chemistry Routes, a Comparing Study  3
K. Rode, T. Kniess, F. Wüst 
 
11The synthesis of [ C]CH3OTf via the “wet chemistry route” (Nuclear Interface module) is compared with the syn-
thesis of [11 11C]CH OTf via gas phase iodination of [ C]CH  (GE TRACERlab FX3 4 c module). The obtained radio-
chemical yields and specific radioactivities are discussed. The N-methylation of a piperazine derivative with 
[11C]CH3OTf performed in the Nuclear Interface module resulted in radiochemical yields of 10 – 27 % and specific 
radioactivities of 60 - 100 GBq/µmol. The reaction in the GE TRACERlab FXc module gave radiochemical yields 
of 5 – 20 % and specific radioactivities of only 5 - 10 GBq/µmol. 
 
Higher radiochemical yields and higher specific 
radioactivities were obtained by the “wet chem-
istry route”. Careful temperature-controlled 
trapping of [
Introduction 
[11C]CH3I and [11C]CH3OTf are important label-
ling precursors for the radiosynthesis of a 
broad variety of PET radiotracers. Using the 
“wet chemistry route”, cyclotron-produced 
[
11C]CO2 before LiAlH4 reduction in 
the Nuclear Interface module proved to be 
advantageous to remove potential carbon con-
taminations in the target gas. Additionally a low 
volume (<0.2 ml) and low concentration (<10 
µmol) of LiAlH
11C]CO2 is reduced by means of 0.05 M LiAlH4 
in THF followed by iodination using concen-
trated HI at 120 °C [1]. [11C]CH3I is converted 
into [11 4-solution should be used to obtain higher specific radioactivities [3].  C]CH3OTf passing over a cartridge con-taining silver triflate at 200 °C. [11C]CH3OTf is 
used for the N-methylation of a piperazine 
derivative. The N-methylated piperazine de-
rivative was purified by semi-preparative HPLC 
and isolated via solid phase extraction on a 
RP18-cartridge. 
The “gas phase method” to produce [11C]CH3I 
is based on the catalytic hydrogenation of 
[11C]CO2 to [11C]CH4 on a Ni-catalyst at 400 °C 
followed by iodination of [11C]CH4 with iodine at 
720 °C in a circulation process. [11C]CH3I is 
trapped on a Porapak Q trap at room tempera-
ture [2]. Subsequent release of trapped 
[11C]CH3I at 190 °C and passage over a 
heated AgOTf-cartridge in a stream of helium 
(6.0) gave [11C]CH3OTf. 
 
Results and Discussion 
[11C]CO2 was produced in an aluminium gas 
target via the 14N[p,α]11C nuclear reaction us-
ing an IBA CYCLONE 18/9 cyclotron. A mix-
ture of nitrogen (6.0) and 0.5 % oxygen (5.5) 
was used as the target gas. In a typical irradia-
tion procedure (40 min, 25 µA) 70 GBq of 
[11C]CO2 were produced at the end-of-
bombardment (EOB).  
Table 1 shows the summary of obtained radio-
chemical yields and specific radioactivities for 
the synthesis of an N-methylated piperazine 
derivative. 
 
Table 1. Radiochemical yields (RCY) and specific radioac-
tivities (AS) at end-of-synthesis (EOS)/C-11 synthesis 
module Nuclear Interface and GE TRACERlab FXc (Har-














For the [11C]CO2/[11C]CH4 conversion in “gas 
phase method”, several Ni-catalysts and tem-
peratures of the Ni-oven have been tested: 
1. Harshaw-Ni: 330, 360 and 400 °C;  
2. Shimalite®-Ni: 360, 400 and 430 °C; 
3. Ni (Aldrich): 400 °C. 
In general, using the GE TRACERlab FXc 
module, significant lower specific radioactivi-
ties were obtained. This is probably mainly 
caused by the reduction of target gas impuri-
ties by the Ni-catalysts to cold CH4. Although 
several Ni-catalysts were tested, maximum 
specific radioactivities of only 10 GBq/µmol 
could be obtained. Beside the proposed car-
bon contaminations originating from the target 
gas, the inorganic matrix of the highly reactive 
Ni-catalysts (Al2O3/SiO2) may also serve as a 
potential source for carbon contaminations 
resulting in low specific radioactivities. 
 
Conclusions 
To obtain higher specific radioactivities with 
the GE TRACERlab FXc module the installa-
tion of a cooling trap is advantageous to freeze 
out the [11C]CO2 before the reduction to 
[11C]CH4. Another possibility might be the ap-
plication of pure Ni-catalyst without any carrier 
material.  
 
Presentation on the 13. Workshop AG Radiochemie, 
Radiopharmazie, Seefeld/Austria, October, 2005. 
 
References 
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Preparation of the Hypoxia-Tracer [18F]FMISO for Medical Use 
P. Mäding, F. Füchtner, J. Zessin, F. Wüst 
 
18The preparation of [ F]FMISO, a well known radiopharmaceutical for imaging hypoxia, was adapted to an auto-
mated module. The synthesis bases on the conversion of the precursor NITTP with a dried mixture of 
[18F]fluoride/K CO2 3/K222 followed by a deprotection step. After HPLC purification, formulation and sterile filtration 
the uncorrected radiochemical yields of [18 18F]FMISO were in the range of 27 - 35 % (related to [ F]fluoride) within 
a synthesis time of 66 min. 
 
Introduction 
Hypoxia in tumours is regarded as an impor-
tant reason behind local failure of radiotherapy. 
Detection and quantification of oxygen levels in 
human tumours may have a significant influ-
ence on the outcome evaluation of patients 
treated with radiation and on the use of hy-
poxia-specific chemotherapeutic agents [1]. 2-
Nitro-imidazole compounds are reduced and 
trapped in hypoxic cells. Therefore imaging 
techniques with radiolabelled 2-nitroimidazole 
derivatives have especially been used as a 
direct marker of oxygen tension in ischemic 
myocardium and tumours [2]. Among these, 
18F-labelled fluoromisonidazole (1H-1-(3-
[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole, 
[18F]FMISO) is now the most widely used radio-
tracer in clinical PET imaging [3]. It is used as 
an in vivo marker of hypoxic cells in tumours 
and ischemic areas of the heart and the brain. 
Therefore we dealt with the preparation of 
[18F]FMISO via a one-pot, two-step synthesis 
procedure according to Fig. 1 using a com-
mercial Tracerlab FXFN synthesis module from 
GE Medical Systems (see Fig. 2). 
 
Results and Discussion 
Several procedures were described for syn-
thesizing [18F]FMISO [4, 5, 6]. The synthesis 
was started from the precursor 1-(2’-nitro-1’-
imidazolyl)-2-O-tetrahydro-pyranyl-3-O-tolue-
ne-sulphonyl-propanediol (NITTP) in the most 
cases. We have also used the conversion of 
the precursor NITTP with a dried mixture of 
[18F]fluoride/K2CO3/K222 in MeCN followed by 
hydrolysis of the tetrahydropyranyl protecting 
group using 1 M HCl. No significant influence 
on the radiochemical yield was found by use of 
5 mg or 10 mg NITTP. Nonconverted [18F]flu-
oride was separated from the reaction mixture 
by means of an Al2O3 cartridge before HPLC 
purification of the [18F]FMISO with a Nucleosil 
100-7 C18 column (EP250/16; Macherey-
Nagel). The eluent was isotonic NaCl : EtOH = 
95 : 5, which was buffered with phosphate 
buffer to pH 7. Under these conditions the 
chemical purity was more reproducible. We 
have also tested a purification method with a 
combination of 3 cartridges (SCX, RP18 and 
Alumina N) instead of HPLC according to [6]. 
But this method was not qualified to obtain a 
pure radiotracer (only 80 % radiochemical 
purity and 3.3 % chemical purity). The sepa-
rated HPLC fraction of [18F]FMISO was diluted 
with isotonic saline followed by sterile filtration. 
In this way a sterile and pyrogen free, in-
jectable solution was obtaind. The uncorrected 
radiochemical yield of [18F]FMISO was in the 
range of 27 – 35 % (related to [18F]fluoride; n = 
13) within a synthesis time of 66 min. Thus, in 
a typical experiment 11 GBq [18F]fluoride could 
be converted into 3.4 GBq [18F]FMISO. For 
clinical use, quality specifications were defined 
in compliance with established pharmaceutical 
rules. Specifications and results of three vali-
dation runs are summarised in Table 1. 
 
Conclusions 
18A procedure for [ F]FMISO production was 
developed based on a module for nucleophilic 
substitution (GE Medical Systems). In this way 
[18F]FMISO could be obtained in reproducible 
yield and purity, which allows the clinical use. 
 
References 
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Table 1. Quality control of [18F]FMISO – specifications and results 
Parameter/method Specification Result (n = 3) 
Appearance (visual) Clear, colourless Clear, colourless 
Identity (HPLC)   ≤  0,5 min Δ t 0.022 ± 0,015 min R
511 ±  25 keV Identity (Gammaspectroscopy) 501 ± 3 keV 
Radiochemical purity (HPLC) ≥ 95 % [18F]FMISO 99.9 % [18F]FMISO 
93.3 ± 2 % FMISO ≥ 90 % FMISO 
+ DH MISO 3.4 ± 0.4 % DH-MISO 
≤ 10 µg FMISO/batch 4.6 ± 0.26 µg FMISO 
Chemical purity (HPLC) 
≤ 1 µg DH-MISO/batch 0.17 ± 0.01 µg DH-MISO 
1 µg/ml acetone ≤ 1000 µg/ml acetone 
Residual solvents (GC/MS) 
1 µg/ml acetonitrile ≤ 410 µg/ml acetonitrile 
Radionuclidic purity (half-life) 1.75 – 1.92 h 1.83 ± 0.006 h 
pH 5.0 – 8.5 7.0 ± 0.06 
Bacterial endotoxines (LAL) < 0.01 I.U./ml ≤ 10 I.U./ml 
Sterility sterile sterile 
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Towards Tc(III)- and Re(III)-Labelled Peptides with Tunable Lipophilicity 
J.-U. Kuenstler, E. Gniazdowska1, H. Stephan, H.-J. Pietzsch 
1Institute of Nuclear Chemistry and Technology, Warsaw, Poland 
 
In order to increase the hydrophilicity of labelled peptides using the “4+1” approach a new "4+1" complex bearing 
three carboxyl groups was synthesised and applied for 99mTc-labelling of a model peptide. 
 
Introduction 
To improve the biobehaviour of 99mTc-labelled 
peptides containing a “4+1” complex as in 
99mTc(NS3)(CN-GGY) (Fig. 2) showing a high 
liver uptake [1], a new hydrophilic “4+1” com-
plex bearing three carboxyl groups was intro-
duced.  
 
Results and Discussion 
The carboxyl-groups bearing ligand 
NS3(COOH)3 (Fig. 1) was synthesised by con-
jugation (DCC) of the dendritically functional-
ised amine H2N-C(-CH2-O-CH2-CH2-COO-Me)3 
[2] to the S-benzyl protected NS3COOH [1] 
















Fig. 1. NS3(COOH)3. 
 
The isocyanide group was coupled to the 
model peptide Gly-Gly-Tyr via an aliphatic 
linker (CN-BFCA). For 99mTc-labelling a two-
step procedure [1] was applied using 99mTc-
EDTA/mannitol (400 MBq) which was reacted 
with 20 µg isocyanide-modified peptide and 
300 µg NS3(COOH)3. 99mTc-labelling resulted 
in a radiochemical yield of app. 25 % (HPLC), 
Fig. 3. The yield can be increased by using a 
higher peptide amount.  
To verify the identity of the 99mTc-labelled pep-
tide the analogous "4+1" Re compound 
Re(NS3(COOH)3)(CN-GGY) was synthesised 






























































99mTc(NS3(COOH)3)(CN-GGY), M = 99mTc, R = H 
Re(NS3(COOH)3)(CN-GGY), M = Re, R = H 
Re(NS3(COOMe)3)(CN-GGY), M = Re, R = Me 
 
Fig. 2. Prepared "4+1" compounds. 
For a convenient synthesis of peptides con-
taining the new hydrophilic Re “4+1” complex, 
the active ester Re(NS3(COO-Me)3)(CN-
BFCA) as shown in Fig. 2 was prepared start-
ing from NS3(COOH)3, [Re(tu)6]Cl3 and 
PMe2Ph followed by ligand exchange with CN-
BFCA. Reaction of Re(NS3(COOMe)3)(CN-
BFCA) with the peptide and hydrolysis of the 




































Fig. 3. Chromatograms of prepared compounds (HPLC, 
Jupiter proteo, eluent: A: MeCN, 0.1 % TFA; B: H2O, 0.1 % 
TFA; gradient elution: 20 to 80 % A in 20 min).  
 
The increased hydrophilicity of the new “4+1” 
complex was shown by HPLC investigations 
(Fig. 3) and determination of the partition coef-
ficient (Log D, octanol/PBS, pH 7.4). 
99mTc(NS3(COOH)3)(CN-GGY) showed a log D 
value of -2.6 ± 0.3 (n = 3) compared with the 
log D value of -1.5 ± 0.2, 99mTc(NS3)-(CN-
GGY). 
As a next step peptides bearing the new “4+1” 




[1] Seifert, S. et al., Bioconjugate Chem. 15 
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Neurotensin Receptor Subtypes: Molecular Characterisation in Adeno- and 
Squamous Cell Carcinoma 
C. Haase, R. Bergmann, M. Baumann1, J. Pietzsch 
1Clinic for Radiotherapy and Radiation Oncology, Medical Faculty Carl Gustav Carus, Dresden University of 
Technology 
 
During the past twenty years peptides and peptide receptors have become an increasing interest in cancerogenic 
processes. Due to the large enrichment of these receptors in many primary human cancers they can be used for 
targeting with radiolabelled peptides for early diagnosis.  
 
Introduction 
Neurotensin receptors (NTR) belong to the 
peptide receptors with great potential in the 
field of molecular targeting since they are 
known to be overexpressed in various tumour 
cell lines including small cell lung carcinoma, 
neuroblastoma, pancreatic or colon cancer. 
Three NT receptors (NTR1, NTR2 and NTR3) 
have been identified to date. NTR1 and NTR2 
belong to the family of G protein-coupled re-
ceptors with seven transmembrane domains, 
whereas NTR3 is a single transmembrane 
domain protein that belongs to a recently iden-
tified family of sorting proteins. In order to ver-
ify the molecular characteristics of the NTR 
subtypes we studied mRNA expression in two 
different tumour cell lines and corresponding 
xenografts [1]. For preparation of total RNA 
from HT-29 (colorectal adenocarcinoma), 
FaDu (squamous cell carcinoma) cells and the 
corresponding xenografts a RNA isolation kit 
was used. The purity and integrity of RNA 
were analysed by measuring the absorbance 
ratio at A260/A280 as well as by electrophoresis 
on a 1 % agarose gel. RT-PCR was performed 
with mRNA as template and 5´ and 3´PCR 
specific primers for the human NTR subtype 
sequences. Products were analysed on a 1.5% 
agarose gel. The expression intensity was 
normalised to house-keeping gene (18S rRNA) 
expression.  
 
Results and Discussion 
NTR1, NTR2 and NTR3 mRNA was present in 
all cells and corresponding xenografts. Tumour 
cells always express higher levels of NTR3 
mRNA compared to NTR1 and NTR2 (Fig. 1). 
NTR3 expression in HT-29 cells was about 
3.5-fold higher to NTR1 and 2.5-fold higher to 
NTR2. Similar results were observed in FaDu 
cells with about fourfold higher expression to 
NTR1 and twofold higher expression to NTR2. 
Moreover FaDu cells overall revealed a higher 
receptor expression than HT-29 (Fig. 1). NTR 
distribution studies in the corresponding xeno-
grafts also revealed a strong expression of 
NTR3 similar to those in tumour cell lines. A 
minor decrease of NTR3 has been detected in 
xenografts compared to cultures cells (Fig. 2). 
NTR mRNA expression levels can be ordered 
as follows: NTR3>>NTR2>NTR1 for cultured 
tumour cells and NTR3>NTR1>NTR2 for the 





Fig. 1. Quantitative PCR analysis of NTR expression in (A) 
HT-29 and FaDu cells and (B) corresponding xenografts. 
NTR expression was normalised to house-keeping gene 
18S rRNA expression. Data are mean ± SD (n = 3). 
 
Our results based on the molecular characteri-
sation give raise to the assumption that NTR 
subtypes are good targets for advanced can-
cer diagnosis, e.g., by using positron emission 
tomography, because of the high mRNA ex-
pression in tumour cells and xenografts [2]. 
 
References 
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In Vitro Neurotensin Receptor Protein Expression in Tumour Tissues and Cells  
C. Haase, R. Bergmann, M. Baumann1, J. Pietzsch 
1Clinic for Radiotherapy and Radiation Oncology, Medical Faculty Carl Gustav Carus, Dresden University of 
Technology  
 
Receptor expression studies by real-time PCR (RT-PCR) indicates that mRNA can be quantified precisely. It 
should be remembered that RT-PCR identifies extremely low message levels that may not translate into the ex-
pression of functional levels of receptors. Understanding the properties of receptor protein will be a helpful tool to 
identify and define radiolabelled ligands for molecular imaging. 
 
Introduction 
Because it is the receptor protein that is tar-
geted in vivo, it should also be the protein that 
is investigated in vitro. In human tumours the 
mRNA and the protein levels for selected pep-
tide receptors may differ, therefore, it is impor-
tant to gain information about receptor protein 
expression. Different methods, e.g., receptor 
autoradiography and immunohistochemistry, 
provide such basic information on receptor 
protein. 
In order to verify the receptor protein expres-
sion of the human neurotensin receptor (NTR) 
subtypes we used two different tumour cell 
lines HT-29 (colorectal adenocarcinoma) and 
FaDu (squamous cell carcinoma) and the cor-
responding xenografts. For Western blot and 
2D-gel electrophoresis membrane proteins 
were extracted by a detergent-based protein 
purification method. Immunoblot analysis was 
done with polyclonal NTR1, NTR2 and NTR3 
specific antibodies and visualised by chemo-
luminescence using a peroxidase conjugated 
secondary antibody. Immunohistochemistry 
was further performed on frozen HT-29 and 
FaDu tumour tissue slices using the same 
antibodies as described above.  
FAST-3,3`diaminobenzidine tablets were used 
as a precipitating substrate for the detection of 
peroxidase activity.  
 
Results and Discussion 
In contrast to mRNA analysis, the correspond-
ing xenografts for FaDu (Fig. 1A) and HT-29 
(Fig. 1E) were strongly immunopositive for 
NTR1. NTR2 (Fig. 1B+F) expression showed a 
weaker reaction compared with NTR1. The 
weakest immunopositive signal was detected 
for NTR3 expression in FaDu (Fig. 1C) and 
HT-29 (Fig. 1G) xenografts. 
Western blotting analysis of purified membrane 
proteins from HT-29 and FaDu cells showed 
similar results compared to xenografts. HT-29 
and FaDu cells were strongly immunopositive 
for NTR1 compared to NTR2 (~50kDa) (Fig. 
2). Western blotting experiments with NTR3 
revealed no detectable signal in both corre-
sponding xenografts. The overall expression of 
NTR1 protein in FaDu xenografts and cells 















A B C D 
E F G H5000 µM
Fig. 1. Immunohistochemistry for NTR in FaDu (A-D) and 
HT-29 (E-H) xenografts for NTR1 (A+E), NTR2 (B+F) and 


















Fig. 2. Immunoblot of 100 ng purified membrane protein 





In conclusion, our results give raise to the as-
sumption that NTR1 is a good target for ad-
vanced cancer diagnosis, e.g., by using posi-
tron emission tomography, because of the high 
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Effects of Oligosaccharide Derivatives on the Metabolism of Tumour Cells 
T. Kampfrath1, B. Schwenzer1, R. Bergmann, J. Oswald 




Our data showed reduced metabolic activity 
and increased apoptosis rates of cultivated 
tumour cells treated with oligosaccharide de-
rivatives and chitosan derived trimers. The 
effects of chitosan trimers were comparable to 
the effects of the oligosaccharide derivatives of 
the marine nature material. 
This study investigates the effect of oligosac-
charide derivatives on proliferation, metabolic 
activity, and apoptosis of cultivated tumour 
cells. The effect of a complex oligosaccharide 
derivative of marine origin with anti-tumour 
activity has been compared with a defined 


























The human bladder carcinoma cell line EJ-28 
was used as tumour model and compared to 
the human fibroblast cell line NHDF 6369. For 
quantification of the glucose metabolism 
[18F]FDG-uptake was measured. The initial 
activity was 60 MBq in 10 ml culture medium. 
The cells were incubated for one hour. The 
incorporated activity was measured with a 
gamma counter. Further we studied the 
programmed cell death with flow cytometry. 
Early phase of apoptosis was detected by 
annexin staining and late phase by propidium 
iodide staining. The protein kinase inhibitor 
staurosporine was used as control substance 
in all experiments. 
      
 
 Fig. 1. [18F]FDG-uptake after 24 hours incubation; compa-
rison between tumour and non-tumour cells. Results 
 
EJ-28 cells treated for 24 hours with oligosac-
charide derivatives and chitosan trimers 




















































18F]FDG-uptake of about 
50 % in comparison to the untreated reference. 
On the other hand, NHDF 6369 incubated with 
these agents, showed an increased [18F]FDG-
uptake up to 150 %. The protein kinase 
inhibitor staurosporine decreased the 
[18F]FDG-uptake to 10 % in both cell lines. 
Furthermore, incubation for 24 hours increased 
the rate of apoptosis. Oligosaccharide deriva-
tives and chitosan trimer were able to raise the 
rate of apoptosis in EJ-28 from 7 % (6 h incu-
bation) to 60 % (24 h incubation). In NHDF 
6369 cells the substances induced an increase 
of apoptosis rates from 15 % (6 h) to 40 % 
(24 h). Staurosporine increased the apoptosis 
rates from 20 % (6 h) to 65 % in EJ-28 and 




Fig. 2. Apoptosis rate after 24 hours incubation; compa-
rison between tumour and non-tumour cells.  
 









Cellular Uptake of Fluorine-18-Labelled Native and Hypochlorite-Modified Low 
Density Lipoproteins (LDL) 
S. Hoppmann, B. Steiniger, C. Haase, J. Pietzsch 
 
Introduction 
Oxidation of LDL apolipoprotein (apo) B-100 
by myeloperoxidase-generated hypochlorite 
(HOCl) is regarded as a crucial event in 
atherogenesis. Recently, HOCl-modified LDL 
(OCl-LDL) has been shown to be present in 
human atherosclerotic lesions [1]. In this report 
we present an improved methodology for ra-
diolabelling of both native LDL (nLDL) and 
OCl-LDL with the positron-emitter fluorine-18 




18 18F]FB-nLDL, [Fig. 2. Cellular uptake of [ F]FB-OCl-
LDL(40 min) and [18F]-SFB) and the use of 18F-fluoro-
benzoylated LDL ([
18F]FB-OCl-LDL(40 h) in HepG2, THP-1 
and HAEC (mean ±  SEM). 18F]FB-LDL) for uptake 
studies in various human cells (Fig. 1) [2]. The 
aim of cellular uptake studies was to scrutinise 
that typical biological properties of [
 
In contrast, human aortic endothelial cells 
(HAEC) take up [18F]FB-nLDL and [18F]FB-
OCl-LDL to the same degree because they 
have both LDL-receptors and scavenger re-
ceptors [3].  
18F]FB-LDL 
have been preserved. Furthermore, possible 
differences in cellular uptake of [18F]FB-nLDL 




18Fig. 1. Proposed reaction scheme for F-radiolabelling of 
LDL with [  18F]-SFB at pH 7.2. As recently proposed, at pH 
7.2 [  18F]-SFB reacts mainly with the chemically accessible, 
deprotonated N-terminal glutamate side chain residue of 
apoB-100 and only to a minor extent with the lysine side 
chain residues that are majorily protonated at pH 7.2 [2]. 
Typically, LDL radiolabelling with [
18 18F]FB-nLDL, [Fig. 3. Cellular uptake of [ F]FB-OCl-LDL 
(40 min) and [18F]FB-OCl-LDL (40 h) in THP-1 cells with 
and without inhibitor (64 nM fucoidan; mean ±  SEM). 
 18F]-SFB resulted in 
radiochemical yields of 30 ± 10 % (nLDL; corrected for 
decay) and 10 ± 5 % (OCl-LDL), respectively, with specific 
radioactivity of 50 - 400 GBq/µmol.  
The cellular uptake of native and modified LDL 
in vitro correlated well with the presence of 
LDL receptors and scavenger receptors in 
different cell types. [
 18F]-SFB labelling of LDL 
and the use of cellular uptake studies provide 
a valuable prerequisite for examinations of the 
metabolic fate of native and oxidised LDL in 
animal models in vivo. 
Results and Discussion 
Cellular uptake studies (Fig. 2 and 3) demon-
strated an enhanced uptake of OCl-LDL in 
human monocytic cell line THP-1 (activated by 
phorbol esters), representing a typical scaven-
ger receptor bearing cell type, when compared 
with nLDL. THP-1 cells treated with fucoidan, a 
specific inhibitor of scavenger receptors class 
A, show a lower uptake of OCl-LDL than un-
treated THP-1 cells. These results indicate that 
[
 
This work is part of the diploma thesis of S.H. (University 
of Wuerzburg, Germany). 
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Catabolism of Hypochlorite-Modified Low Density Lipoproteins (LDL) In Vivo: 
Insights from Small Animal PET Studies 
S. Hoppmann, B. Steiniger, C. Haase, J. Pietzsch 
 
Introduction 
Oxidative modification of LDL apolipoprotein 
(apo) B-100 by myeloperoxidase-generated 
hypochlorite (HOCL) is regarded as a crucial 
event in atherogenesis. In this report we pre-
sent the use of [18F]-fluorobenzoylated LDL 
particles ([18F]FB-LDL) in dynamic small ani-
mal PET studies in rats.  
 
Results and Discussion  
The method was initially evaluated with re-
spect to the uptake of [18F]-fluorobenzoylated 
native ([18F]FB-nLDL) and oxidised LDL 
([18F]FB-OCl-LDL) in various human cells      
[1, 2]. As a result, radiolabelling of native and 
modified LDL using [18F]-SFB caused no al-
teration of their biological activity and function-
ality in vitro. Biodistribution studies in rats re-
vealed high in vivo stability for the [18F]FB-LDL 
(data not shown in detail). The metabolic fate 
of ([18F]FB-nLDL and ([18F]FB-OCl-LDL in vivo 
was delineated by dynamic PET studies     
(Fig. 1).  
 
 
Fig. 1. Representative time-activity-curves showing in vivo 
kinetics of 18F-radioactivity concentration after i.v. injection 
of either [18F]FB-nLDL or various species of [18F]FB-OCl-
LDL in rats (blood, top; spleen, bottom left; liver, bottom 
right) as calculated from region-of-interest (ROI) analysis 
of dynamic small animal PET scans. 
 
The in vivo distribution and kinetics of both 
native and modified LDL particles in the rat 
correlated well with the anatomical localization 
of LDL receptors and scavenger receptors 
(Fig. 2). As an important result, dynamic PET 
studies in rats revealed a strongly enhanced 
catabolism of [18F]FB-OCl-LDL when com-
pared with [18F]FB-nLDL. In this line, the high 
accumulation of [18F]FB-OCl-LDL in liver and 
spleen is supposed to be attributed to the 
scavenger receptor activity of endothelial cells 
and resident macrophages in these organs, 
e.g., hepatic Kupffer cells and splenic marginal 
zone macrophages. In contrast, the major 
binding sites of [18F]FB-nLDL particles are LDL 
receptor carrying hepatocytes, adrenal cells as 




Fig. 2. Representative whole body PET scans showing 
18F-radioactivity distribution (120 min p.i.) after i.v. injection 
of either [18 18F]FB-nLDL (left) and [ F]FB-OCl-LDL (40 min) 
(right) in rats. 
 
The results of the present in vivo examinations 
show that circulating OCl-LDL were cleared 
very effectively and fast by the reticuloendo-
thelial system (RES). These investigations are 
of value for further evaluation of circulating 
oxidatively modified LDL as a potential indica-
tor for oxidative stress and atherosclerotic risk 
[2]. [18F]SFB-labelling of LDL and the use of 
small animal PET provide a valuable tool to 
discriminate the kinetics and the metabolic fate 
of both native and oxidised LDL in animal 
models in vivo. 
 
The authors are grateful to Mareike Barth and Regina 
Herrlich for their expert technical assistance. This work is 
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Protein Oxidation in Human Disease: Prediabetes and Diabetes Mellitus Type 2 
J. Pietzsch, C. Haase 
 
Hyperglycemia increases the formation of both oxidised low density lipoproteins (oxLDL) and gly-
cated/glycoxidised LDL (glycLDL) which are important modulators of atherosclerosis and cardiovascular death. 
Recent advances in our understanding of oxidative and glycative stress under hyperglycemic conditions in vitro 
and in vivo have included: identification by mass spectrometry of the chemical nature of specific oxidative and 
glycative modifications in LDL, identification of oxLDL/glycLDL in disease-related tissue compartments and estab-
lishing the role of specific receptors that recognize oxLDL/glycLDL. This minireview summarises some recent 
results providing further evidence that both oxidation and glycation of human LDL play a pivotal role in the patho-
genesis of atherosclerosis in prediabetes and diabetes mellitus Type 2. 
 
Patients with overt diabetes mellitus Type 2 
and subjects with prediabetes, e.g., impaired 
glucose tolerance, are at very high cardio-
vascular risk. In atherogenesis oxidatively 
modified LDL (oxLDL) play a crucial role. LDL 
oxidation is a major event occurring within the 
vascular wall, which transforms LDL into cyto-
toxic agents able to promote complex se-
quences of proatherogenic events that partici-
pate to endothelial dysfunction, smooth muscle 
cell migration and proliferation, chemoattrac-
tion of inflammatory mononuclear cells, and 
apoptosis of vascular cells. The biological 
properties of oxLDL depend on the presence 
of oxidatively modified lipids and apolipopro-
teins, and on their uptake by cells through 
specific receptors. The excessive uptake of 
oxLDL via scavenger receptors in macro-
phages, vascular smooth muscle cells, and 
endothelial cells in an unregulated fashion 
leads to foam cell formation. The presence of 
foam cells in the vascular wall is considered to 
be the first morphological substrate of athero-
sclerosis. In contrast, native LDL (nLDL) will 
not promote the formation of foam cells under 
most circumstances, as uptake of nLDL by the 
LDL receptor pathway results in down-
regulation of endogenous cholesterol synthesis 
and LDL receptor expression. Growing evi-
dence indicates that oxidative modification of 
LDL is strongly increased both in subjects with 
prediabetes and in patients with overt diabetes 
mellitus Type 2, thereby implicating hypergly-
cemia as a causative factor [1, 2]. However, 
the mechanisms underlying the relation be-
tween hyperglycemia and increased LDL oxi-
dation are not fully understood. LDL particles 
can undergo several oxidative modification 
reactions all of which are facilitated under con-
ditions of high glucose-induced oxidative 
stress. On the one hand, the lipid constituents 
of the LDL particle are oxidised by reactive 
oxygen species. On the other hand, the major 
structural protein of LDL, apolipoprotein (apo) 
B-100, can also be oxidatively modified either 
by covalent binding to lipid peroxidation prod-
ucts or by direct oxidation of its amino acid 
side chain residues [3]. Glucose itself can di-
rectly modify apoB-100 amino acid residues in 
a process called glycation or glycoxidation [4]. 
However, the nature of specific modifications 
of protein amino acid residues altering their 
cellular functions still remains a subject of de-
bate. Exemplarily, evidence for the important 
role of transition-metal catalysed processes in 
diabetes-associated lipoprotein oxidation is 
emerging [5]. However, no consensus has 
been achieved on whether these processes 
involving both copper and iron interact with the 
glycation/glycoxidation mechanism, or are 
independent. One recent study found the lack 
of any further stimulation of Cu2+-induced lipid 
peroxidation or protein oxidation by glucose 
[4]. Others described increase of both Cu2+-
mediated LDL oxidation and the chemotactic 
activity of oxidised LDL towards pro-
inflammatory cells by glucose in a concentra-
tion-dependent manner [6]. The incubation 
with glucose alone, under the conditions of 
very minor oxidation, also increased the 
chemotactic properties of LDL particles. In 
another study [7], glucose induced formation of 
conjugated dienes and thiobarbituric acid re-
acting substances and increased LDL electro-
phoretic mobility, also in a concentration-
dependent manner. Some of these effects of 
glucose have been observed in the model of 
iron-mediated LDL oxidation [8]. Whereas the 
in vivo availability of free copper or iron ions is 
under tight control under normal physiological 
conditions, these transition metal imbalances 
are well documented in diabetes mellitus. For 
this reason, oxidation systems containing 
complexed, porphyrin-bound redox active iron 
are considered experimental models of high 
pathophysiological relevance [9]. These sys-
tems involve binding of, e.g., hemin (Fe3+-
protoporphyrin IX), a blood product and a 
physiological source of iron, to discrete binding 
sites of LDL and apoB-100, respectively, thus 
forming centers for redox cycling and repeated 
radical production and subsequent oxidation of 
LDL [9]. For apoB-100 these modifications 
finally result in the formation of new epitopes, 
e.g., by formation of apoB-100 crosslinks and 
loss of free amino groups. Recently, in vitro 
studies revealed that hemin induces oxidation 
of both proline and arginine residues of apoB-
100 with the formation of γ-glutamyl semialde-
15 
hyde (γGSA) which can be easily reduced to 
the stable product 5-hydroxy-2-aminovaleric 
acid (HAVA) [9, 10]. Very recently, assessment 
of HAVA by a sensitive GC-MS approach also 
was employed to test the hypothesis that re-
dox-active glucose further stimulates transition 
metal-induced LDL apoB-100 oxidation [11]. 
We performed in vitro studies to i) identify po-
tential mechanisms of HAVA formation in LDL 
apoB-100, using various well-characterised 
oxidation systems, and ii) to explore the effects 
of increasing concentrations of glucose on 
hemin-induced γGSA formation. These studies 
showed that glucose markedly enhanced the 
hemin-mediated oxidation process in a con-
centration-dependent manner. This effect is 
probably mediated via acceleration of the re-
dox cycling of coordinatively bound Fe3+ due to 
enhanced reduction of iron by glucose. The 
stimulating effect of physiological and patho-
physiological concentrations of glucose on the 
hemin-catalysed LDL apoB-100 oxidation ap-
peared superoxide-dependent, and was com-
pletely inhibited by manganese superoxide 
dismutase. Thus, glucose mediates reduction 
of complex-bound iron via superoxide-depen-
dent mechanism. In contrast, in the absence of 
glucose the hemin-catalysed LDL apoB-100 
oxidation was not affected by the manganese 
superoxide dismutase, thus pointing to the fact 
that the redox cycling of coordinatively bound 
ferric iron is superoxide-independent [11]. We 
have also assessed LDL apoB-100 HAVA 
concentrations in vivo, in subjects with normal 
and impaired glucose tolerance as well as with 
clinically manifest diabetes mellitus. These 
studies revealed markedly elevated LDL apoB-
100 HAVA levels in patients with prediabetes 
and overt diabetes mellitus Type 2 compared 
to healthy normolipidemic and normoglycemic 
individuals [11]. The LDL HAVA levels in pa-
tients with diabetes mellitus in this present 
study appeared remarkably similar to those in 
circulating LDL of hypercholesterolemic sub-
jects with a high risk for atherosclerosis [12]. 
Recently, γGSA formation has also been dem-
onstrated in LDL apoB-100 in atherosclerotic 
lesions [13]. thus providing additional informa-
tion implicating oxidative modification of LDL 
apoB-100 proline and arginine residues in the 
development of atherosclerosis. In conclusion, 
our in vitro studies provide evidence of super-
oxide-mediated glucose enhancement of the 
hemin-induced LDL apo-B-100 oxidation [11]. 
The latter is consistent with the in vivo evi-
dence of enhanced iron-mediated LDL oxida-
tion in the diabetic and prediabetic state. Our 
findings suggest that elevated plasma glucose 
concentrations provide a major contribution to 
increased formation of circulating modified LDL 
particles in subjects with prediabetes and overt 
diabetes mellitus Type 2. Glucose-enhanced 
LDL apoB-100 oxidation may represent one 
mechanism of increased atherosclerosis in 
these subjects. However, further studies are 
needed to understand both the nature of the 
original oxidative insult and the specific conse-
quences of formation of γGSA or other specific 
oxidation products for the metabolic fate of 
apoB-100-containing lipoproteins in vivo. 
Moreover, the role of circulating modified LDL 
species in disease is of particular interest. In 
this line, the development of novel methodolo-
gies for radiolabelling of nLDL and various 
species of modified LDL, including oxLDL and 
glycLDL, with 18F or other positron emitting 
nuclides and the use of small animal PET to 
investigate the metabolism of these several 
lipoprotein species in vivo is currently in pro-
gress [3, 14-16]. 
The authors wish to thank Mareike Barth, Susan 
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Monitoring of Stem Cell Homing with Small Animal PET  
J. Oswald, R. Bergmann 
 
Stem cells and progenitor cells are widely used in therapeutic approaches, e.g., for the reconstitution of the hema-
topoietic system during the therapy of leukemia. We show here the feasibility of tracking labelled hematopoietic 




Bone marrow derived hematopoietic stem cells 
are widely used for the therapy of various ma-
lignancies like leukemia or other neoplasia. 
Following myeloablative chemotherapy, which 
eliminates both tumour cells and bone marrow 
cells of the patient, donor hematopoietic cells 
can be transplanted, which then migrate from 
the peripheral blood to the bone marrow. This 
process is generally termed “homing”, because 
the transplanted donor cells migrate autono-
mously to their native environment, i.e. the 
bone marrow of the host [1]. In our approach 
we wanted to monitor the early steps of blood 
stem cell homing utilising positron emission 
tomography (PET). We therefore labelled hu-




Fig. 1. Biodistribution of [18F]FDG labelled hematopoietic 
stem cells after 4 hours (left figure: colors normalised to 
the maximum; right figure: color scale expanded to 
visualise also the low activity areas). 18F]fluorodesoxyglucose ([18F]FDG) 
and transplanted them in NMRI nude mice, 
which comprises a valuable mouse model for 
xenotransplantations, i.e the transfer of human 
or other non-murine cells in mice. The biodis-
tribution of the labelled cells was then moni-




Results and Discussion 
Human hematopoietic stem cells (a kind gift of 
Prof. Denis Corbeil, Biotechnologisches Zen-
trum der TU Dresden) were isolated using 
immunomagnetic beads. 1x106 were then ra-
diolabelled with 20 MBq [18F]FDG for one hour 
in glucose-free medium. Approximately 20 KBq 
per cell preparation could be applied to the 
anesthesised mice. Using the microPET
 
 
Fig. 2. Kinetics of the labelled cells in the lung.  ® P4 
the biodistribution of the cells was observed for 
four hours. The time activity curves in the in-
terested organs were derived from 3D regions 
of interest by the program ROIFinder and ana-
lysed using the program system R. Data 
analysis revealed that the majority of cells first 
migrated into the lungs where they were cap-
tured in the small vessels. Subsequently, cells 
also migrated to liver, spleen and kidney.  
 
 
Future experiments with either different meth-
ods like the direct labelling of cells with 
[18F]SFB or other radionuclides with longer 
half-lives might improve the labelling efficiency 
which then will allow an extended monitoring of 
stem cell homing.  
 
References Our data showed the feasibility of stem cell 
tracking utilising small animal PET. The PET 
tracer [
[1] Lapidot, T. et al., Blood 106 (2005) 1901-
1910. 18F]FDG might not be the optimal label, 
because the efficiency of the metabolic label-
ling with [
 
18F]FDG was very low . 
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Biochemical Characterisation of Fluorescein-Labelled Neurotensin Derivatives 
R. Bergmann, V. Maes1, Ch. Hultsch, S. Kohl, Th. Hanke2 1 , D. Tourwé
1Organic Chemistry Department, Vrije Universiteit Brussel, Belgium, 2Institut für Materialforschung, TU Dresden 
 
Neurotensin(8-13) analogues containing a glycine or 5-aminovaleroyl spacer were labelled with fluorescein 
through formation of a N-terminal thioureum function. The receptor binding was measured in HT-29 cell cultures 
and showed a substantial decrease in affinity, especially for the metabolically stabilised [MeArg9, Tle11] ana-
logue. Using fluorescence microscopy, the internalisation of the fluorescent neurotensin analogues into HT-29 
cells was observed. 
 
Introduction Fluorescence microscopy 
HT-29 cells were incubated with the neuro-
tensin analogues and after removal of the in-
cubation liquid the cells were examined using 
a wide-field fluorescence microscope. After 
binding to the neurotensin receptor, the recep-
tor-ligand complex is internalised. 
In recent years it has become evident that 
neuropeptide receptors allow the successful in 
vivo targeting of many tumours. A major limita-
tion of the use of neuropeptides as targeting 
molecules is their rapid degradation by plasma 
and tissue proteases. As an extension of our 
studies on radiolabelled neurotensins for tu-
mour diagnosis and therapy, we here present 
our results on the characterisation of fluo-
rescein-labelled neurotensin analogues, and 
their uptake in HT-29 tumour cells. 
 
 
Results and Discussion 
Design and synthesis of peptides 
An influence of the fluorescein group that is 
linked through a thiourea function to the pep-
tide cannot be excluded. Therefore, a Gly 
spacer and a longer 5-aminovaleroyl (Ava) 
spacer were inserted. The FITC group was 
introduced by reaction with fluorescein isothio-
cyanate.    
 Fig. 2. The image represents a superposition of the blue 
and green channel images. In this figure the FITC-labelled 
ligand 2 appears in a light greenish colour. 
Table 1. Peptide structure of FITC-neurotensin analogues. 
 
 NT Neurotensin 
NT(8-13) Arg-Arg-Pro-Tyr-Ile-Leu-OH 
1 FITC-Gly-Arg-Arg-Pro-Tyr-Ile-Leu-OH 
2 FITC-Ava-Arg-Arg-Pro-Tyr-Ile-Leu-OH  
3 FITC-Ava-Arg-MeArg-Pro-Tyr-Tle-Leu-OH  
The introduction of a fluorescein group at the 
N-terminus of NT(8-13) reduces the receptor 
affinity. The modifications of the peptide se-
quence in order to limit the metabolic break-
down further reduce the receptor affinity, in 




The affinity of the peptides for the NTR-1 was 
determined in HT-29 cells. 99mTc-labelled analogues. Nev-
ertheless, for the most potent analogue 1 the 
internalisation into HT-29 cells can be visual-
ised using confocal microscopy. The applica-
tion of a fluorescently labelled NT analogue will 
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Implementing a Small Animal Magnetic Resonance Imaging System 
K. Strobel, R. Bergmann, J. van den Hoff 
 
The implementation of Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy for small animals at 
the PET-centre is described. 
 
 
The image fusion of MRI and PET allows the 
identification of the anatomical regions of in-
creased tracer uptake. The image fusion of the 
PET and MRI was performed using the Multi 
Purpose Imaging Tool (MPI Tool, ATV GmbH, 
Germany). 
Introduction 
Since January 2005 a small animal Magnetic 
Resonance Imaging system with magnetic field 
strengths of 7 T (BioSpec™ 70/30, Bruker 
Biospin MRI GmbH, Ettlingen, Germany) oper-
ates at the PET-centre. The information ob-
tained by Magnetic Resonance Imaging (MRI) 
and Spectroscopy (MRS) are complementary 
to that obtained by Positron Emission Tomo-
graphy (PET). The combination of the ana-
tomical and morphological information of MRI 
and the functional information of the PET data 
allows a better understanding of tumour biol-
ogy and metabolism. 
Moreover, measurement protocols for localised 
spectroscopy (e.g. PRESS) in very small vol-
umes (~ 2 x 2 x 2 mm) were tested and im-
proved for proton (1H) MRS. First spectra were 
derived from human xenograft tumours trans-
planted in nude mice (Fig. 2).  
 
Results and Discussion 
In the framework of the implementation of the 
MRI system, own measurement protocols were 
created (e.g. t1-weighted, t2-weighted), to get 
optimal contrast in various organs and/or tis-
sues (e.g. tumours, vascular system). 
Furthermore, a file conversion tool was devel-
oped and implemented to convert two and 
three dimensional data from the MRI file format 
to a file format which is compatible to the PET 
file format (here: ECAT7). This was done to 
allow the fusion of anatomical and morphologi-
cal MRI data and the functional PET data with 
existing software (Fig. 1).  
 
 
Fig. 2. PRESS proton spectra (TR = 1.2 s, TE = 20 ms, 
1200 Averages) on a 1.5 x 1.5 x 1.5 mm voxel of a tumour 
xenograft on the leg of a nude mouse. 
 
The choline peak at 3.2 ppm is typical for 
growing tumour cells. This information together 
with the information acquired from the radio 
tracer PET data yield a more complete picture 
of the tumour metabolism. 
 
Conclusions 
MRI and MRS provide valuable information, 
complementary to that obtained with PET, thus 
allowing a better assessment of tumour biol-
ogy, structure and metabolism.  
 
 
Fig. 1. The image fusion (lower row) of PET (upper row) 
and MRI (middle row) of a tumour xenograft on the leg of a 
nude mouse is shown. 
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Optimised List-Mode Acquisition and Data Processing Procedures for ACS2 
Based PET Systems 
J. Langner, P. Bühler, U. Just, C. Pötzsch, E. Will, J. van den Hoff 
 
Introduction 
Modern positron emission tomography (PET) 
scanners usually acquire data in so-called 
histogram-mode, where all coincidences are 
sorted online into three-dimensional histo-
grams. This saves storage space and mini-
mises the required bandwidth, but it also 
represents a loss of information. Therefore, 
PET scanners like the ECAT Exact HR+ allow 
for the acquisition of data in a separate mode, 
called list-mode. Based on this data, methods 
aiming at the modification of the coincidence 
events information can be applied prior to the 
image reconstruction, e.g. for correction of 
patient motion [1]. However, several aspects 
hinder the routine use of list-mode. For exam-
ple, the limited network capabilities of the un-
derlying acquisition control system (ACS2) 
lead to long time delays of up to several hours. 
As a result, the image data is often available 
only the next day, thus representing an unac-
ceptable delay for clinical PET. To overcome 
these obstacles, we have developed custom 
hardware and software. These methods do not 
only allow for the integration of list-mode in 
routine operation, they also improve the overall 
runtime stability of ACS2-based PET systems, 
making them also attractive for histogram-
mode acquisitions.  
The ACS2 usually stores the acquisition data 
on an internal SCSI-2 hard disk. Although this 
bus type supports a maximum theoretical 
throughput of 10 MB/s, the ACS2 does not 
allow for the transfer of data to other systems 
with rates higher than ≈ 0.5 MB/s. We replaced 
the internal hard disk of the ACS2 with a dual-
channel Ultra160-SCSI RAID. To arrange for a 
parallel access from another machine, we 
connected the second channel of the RAID 




Fig. 1. Using a dual-channel Ultra160-SCSI RAID storage 
device, it is possible to access the stored acquisition data 
from another system in parallel with a maximum through-
put of ≈ 70 MB/s. 
 
Furthermore, to be able to access the data 
from the Linux system, we reverse-engineered 
the structure of the used file system and de-
veloped an own implementation. Although this 
solution accesses data considerably faster, the 
PET system still has to be explicitly switched 
into another acquisition mode prior to each list-
mode acquisition. To improve this situation, we 
verified the routing of the raw coincidence data 
on the ACS2 by sampling it from externally 
accessible data cables using a digital oscillo-
scope. In order to permanently sample the 
data we have developed a separate hardware 
adapter card. It uses optoelectronic couplers 
and allows, together with two PCI-based digital 
data acquisition cards (DAQ), to retrieve all 




Fig. 2. Two digital acquisition cards (DAQ) are used in a 
Linux system to acquire the raw data in parallel and to 
save it to a separate hard disk (HD) device. 
 
Results and Discussion 
Our hardware based acquisition methods over-
come certain long-term hardware limitations of 
the ACS2 of the ECAT Exact HR+ PET Scan-
ner series. After implementation, we were able 
to observe a high speed-up. The methods 
allow to transfer stored data from the ACS2 to 
another system with a max. throughput of ≈ 70 
MB/s, a 140× speed-up in comparison to the 
ACS2’s original capabilities. For list-mode ac-
quisitions, such a speed improvement means 
that a typical data transfer requires only ≈ 1 
min in contrast to the previously ≈ 2.5 h for an 
amount of ≈ 4 GB of data (one hour 18F-FDG 
@ ≈ 330 MBq). In addition, the immediate 
transfer of the acquired data also improves the 
general runtime stability of the ACS2, and thus 
is also attractive for conventional histogram-
mode acquisitions. Moreover, by using our 
DAQ-based acquisition solution, the ECAT 
Exact HR+ can be operated in conventional 
histogram-mode, while a concurrently running 
Linux system reads out the raw list-mode 
stream in real-time. This, in combination with 
our software solutions, permits to integrate list-
mode in clinical PET investigations. 
 




[1] Langner, J. et al., Annual Report 2004, 
FZR-424, p. 12. 
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User Guided Segmentation and Quantification of Three-Dimensional Structures 
in Oncological Whole Body PET - Continued 




In the last report [1] we described a tool for 
analysis and quantification of volumes of inter-
est (VOI) in three-dimensional tomographic 
datasets which are obtained by positron emis-
sion tomography (PET). This tool has several 
advantages compared to other programs on 
the market, like a comfortable viewer with 
three different views, threshold based three 
dimensional VOI evaluations, export filters for 
the statistic values and the availability for dif-
ferent operation systems (Windows, MacOS X 
and Unix/Linux). 
 
Because of technical improvements in the area 
of PET and PET/CT, and the upcoming usage 
of PET datasets in treatment planning some 
additional features where implemented this 
year. One aim was the handling of several 
studies at once to allow simultaneous delinea-
tion of VOIs at identical locations in different 
studies. Moreover, user-independent segmen-
tation was a field of our research. 
 
Results and Discussion 
To achieve the aforementioned, a multi study 




Fig. 1. Parallel display of a follow up study.  
 
This parallel display allows the user to view 
and process 2 or more studies at the same 
time. All operations like mask creation or VOI 
evaluation which are performed on one of the 
images are done in parallel on the others. Dif-
ferent PET scans usually imply different posi-
tioning of the patient. To achieve an optimal 
alignment of the images the corresponding 
volume data are coregistered, where the 
alignment is measured by the mutual informa-
tion of the data. Consequently, the user can 
work on PET and CT studies at the same time 
to combine the information provided by the 
different modalities like the morphology in CT 
and the metabolism in PET. Additionally this 
allows the comparison of VOIs in two PET 
studies at different times to assess treatment 
success or failure. 
 
To use other modalities the import filters were 
rewritten. Currently, images of the Concorde 
microPET and Siemens ECAT7 are supported. 
To be more manufacturer independent the 
DICOM protocol can be used to import files 
from hard disk and over network. 
 
The automatic threshold based segmentation 
uses a new target/background algorithm and a 
contrast-based threshold [2] to identify the 
VOIs independently of the user. This ensures 
minimal Inter-Observer variability and gener-
ally leads to stable and reproducible results. 
 
For a better integration in routine work and the 
intended commercialisation of the program in 
cooperation with ABX Radeberg (Advanced 
Biochemical Compounds, Radeberg) a com-
prehensive online help, a licensing system and 
installers for various operation systems have 
been implemented. 
 
Future developments will aim at improving 
export and import of the resulting data (masks, 
VOIs,…) which gives the user the ability to 
save time by defining templates or reload pre-
viously analysed studies. Further improvement 
of the segmentation algorithm should further 
stabilise the results in most circumstances. 
 
References 
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A Novel Rhenium Chelate System Derived from Dimercaptosuccinic Acid 
1T. Heinrich, W. Kraus , H.-J. Pietzsch, C. Smuda, H. Spies 
1
Bundesanstalt für Materialforschung und –prüfung, Berlin  
 
A novel type of tetradentate ligand derived from DMSA has been synthesised. The tetrathiolato S4 ligand forms 
anionic five-coordinated oxorhenium(V) complexes with square-pyramidal coordination geometry. The orientation 
of the metal oxo group is exo in relation to the carbamido groups of the ligand. 
 
Introduction 
This work is part of our efforts to develop che-
lating agents for stable binding and easy con-
jugation of rhenium-188 to targeting molecules. 
Keeping in mind the high in vivo stability of 
[
188
ReVO(DMSA)2]- [1] we want to exploit this 
coordination system for the synthesis of novel, 
even higher stable 188ReVO–S4-chelates.  
 
Results and Discussion 
A new type of tetradentate ligand has been 
synthesised starting with meso-DMSA by 

































The resulting stereoisomeric tetrathiolato 
S4-ligand 1 of the composition (i-Bu)2N(O)C-
C(SH)-C(SH)-C(O)NH-(CH2)3–NH-(CH2)3–
NHC(O)-C(SH)-C(SH)-C(O)N(i-Bu)2 forms an-
ionic five-coordinated oxorhenium(V) com-
plexes 2 and 3 by ligand exchange reaction of 
NBu4[ReOCl4] in methanol. The mixture of 
isomers as indicated by HPLC was separated 
by chromatographic methods.  
X-ray crystal structure determination of both 
stereoisomeric forms reveals the square-
pyramidal coordination geometry of the Re
VOS4 core. The equatorial plane is formed by 
four thiolate sulfur atoms, whereas the oxygen 
occupies the apical position. The orientation of 
the metal-oxo core is exo in relation to the 
carbamido groups in both isomers. Both com-
plexes are stereoisomeric regarding the junc-
tion of the triamine chain. Compound 2 is the 
exo-trans and compound 3 is the exo-cis iso-
mer. 
In the absence of base, the oxorhenium(V) 
compounds were isolated as “betaine”, with 
the protonated nitrogen of the bridge serving 























Optimised Procedure for Preparing 188Re(V) Complexes under Mild Conditions 
S. Seifert, H.-J. Pietzsch  
 
188An easy and gentle method for the preparation of Re(V) complexes with bidentate and tetradentate ligands is 
described starting from the precursor complex 188Re(III)-EDTA.  
 
Introduction 
Complexes of 188Re(V) are commonly synthe-
sised by a one-step route using huge amounts 
of auxiliary ligands (oxalic acid, cyclodextrines, 
citric acid, tartaric acid, ethylene diamine tetra-
acetic acid), reducing agents and in most 
cases also high temperatures. Another way to 
prepare the desired 188Re(V) complexes is a 
two-step procedure, in which, for example, a 
glucoheptonate, gluconate or citrate complex 
is first formed, and then in a second step un-
dergoes a ligand exchange reaction with the 
appropriate ligand. Moreover, we found that 
188Re(III)-EDTA also represents a suitable 
precursor for the preparation of 188Re(V) oxo 
and dioxo complexes. 188Re(III)-EDTA can be 
prepared in acidic solution at room tempera-
ture and in volumes of 1 - 10 ml [1]. The com-
plex is stable to only a limited extent and is 
easily re-oxidised to perrhenate in neutral solu-
tions. Considering this distinctive re-oxidation 
behaviour of 188Re(III)-EDTA it should be pos-
sible to prepare 188Re complexes of higher 
oxidation states by a combined ligand ex-
change/re-oxidation reaction with suitable 
ligands. This work presents a simple method 
for the preparation of oxorhenium(V) com-
plexes as [ReO(ECD)], [ReO(DMSA)2]-, or 
[ReO(MAG3)]- (ECD = L,L-ethylene dicysteine 
diethyl ester, DMSA = dimercapto succinic 
acid, MAG3 = mercaptoacetyl triglycine) and 
dioxorhenium(V) complexes as [ReO2(en)2]+, 
[ReO2(tau)]+ or [ReO2(cyclam)]+ (en = ethylene 
diamine, tau = 1,4,8,11-tetraazaundecane, 
cyclam = 1,4,8,11-tetraazacyclotetradecane) 
using the precursor complex 188Re(III)-EDTA.  
 
Radiolabelling 
188Re(III)-EDTA was prepared by adding 3 – 5 
ml perrhenate eluate from a 188W/188Re gen-
erator together with 0.05 ml 1 M HCl to a kit 
vial containing 5 mg EDTA, 5 mg mannitol and 
1.0 mg SnCl2 in freeze-dried form under nitro-
gen. After 20 - 30 min at room temperature the 
complex formation was finished; yield: > 95 % 
(TLC). Alternatively, the same complex was 
prepared using BER (BER = borohydride ex-
change resin) instead of SnCl2 as the reducing 
agent [2]. For this purpose a mixture of 5 mg 
EDTA and 5 mg mannitol dissolved in 0.5 ml 
saline, and 2 ml perrhenate eluate containing 5 
µl of 85 % H3PO4, was added to a vial contain-
ing 10 mg BER under nitrogen. After 25 min 
reaction time at room temperature 90 - 95 % of 
the desired complex was formed. 
For preparation of the 188Re(V) complexes 0.1 
– 10 mg of the appropriate ligand dissolved in 
1.0 ml of 0.1 M phosphate buffer solution of pH 
7.4 or 9 – 10 was added under nitrogen flush-
ing to 1.0 ml of the acidic precursor solution 
and the final solution was allowed to stand for 
10 – 20 minutes at room temperature. In most 
cases an ultrasonic bath was used for incuba-
tions.  
 
Results and Discussion 
We found that [188Re]perrhenate is easily re-
duced to a 188Re(III)-complex without heating 
and with only 1 mg of stannous chloride in an 
acidic solution of EDTA, also in volumes of 10 
ml. To avoid the undesired formation of stan-
nous hydroxides, SnCl2 may be substituted by 
BER. Using optimised conditions the resulting 
188Re(III)-EDTA solution exhibits the same 
radiochemical purity, about 95 %, as that de-
termined for a Sn(II)-reduced solution. More-
over, the BER is easy to remove from the 
complex solution. The re-oxidation studies per-
formed with bidentate and tetradentate ligands 
resulted in high yields of the desired 188Re(V)-
oxocomplexes when the ligands DMSA or 
ECD were dissolved in 0.1 M phosphate buffer 
pH 7.4 and added, with the exclusion of air, to 
the acidic 188Re(III)-EDTA solution (Table 1). 
Thus, the ligand exchange reaction between 
188Re(III)-EDTA, which was prepared under a 
nitrogen atmosphere in the kit vial, and the 
respective ligand occurs in neutral solution and 
only small amounts of perrhenate are formed. 
However, when the preparations were per-
formed without the exclusion of air and after 
neutralisation of the 188Re(III)-EDTA solution, 
20 – 30 % perrhenate was always detected in 
the final solution. Obviously, the neutralisation 
of the 188Re(III)-EDTA solution must be carried 
out in the presence of the appropriate ligand in 
order to prevent a fast re-oxidation of 188Re(III)-
EDTA to perrhenate. The identity of the pre-
pared 188Re complexes was confirmed by si-
multaneously prepared and well-characterised 
99mTc complexes and cold rhenium complexes. 
188Re(V)-DMSA prepared from 188Re(III)-EDTA 
at room temperature was compared by HPLC 
with “kit-prepared” 99mTc(V)-DMSA and the 
other preparations were identified in the same 




188 188Re(V) complexes from Re-EDTA   Table 1. Yields and reaction conditions for the preparation of 
 
Complex formed Yield [%] Optimum reaction conditions 
[188ReO(ECD)] 95 ± 2 0.5 mg ligand, ultrasonic, 10 min, pH 7, N2
[188ReO(DMSA)2]- 94 ± 3 0.5 mg ligand, ultrasonic, 10 min, pH 7, N2
[188ReO(MAG3)]- 95 ± 2 0.5 mg ligand, ultrasonic, 10 min, pH 9 
[188ReO2(en) ]+ 93 ± 2 10 mg ligand, ultrasonic, 10 min, pH 10 2
[188ReO2(tau)]+ 94 ± 2   5 mg ligand, ultrasonic, 10 min, pH 10 
[188ReO2(cyclam)]+ 50 ± 5 20 mg ligand, ultrasonic, 10 min, pH 10, N2  
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6
(min)   
 
188Fig. 1. Comparison of HPLC analyses of Re(V)-DMSA and a kit preparation of 99mTc(V)-DMSA; PRP-1 column; aceto-
nitrile/0.1 % TFA (A)//water/0.1 % TFA (B); all three stereoisomers are well separated using a linear gradient 0 to 50 % A in 20 
min (Rt values between 8 and 13 min). 
 
The cationic dioxocomplexes with acyclic and 
cyclic polyamines were prepared according to 
the same procedure. The preparation of the 
complexes [188ReO2(en)2]+ and [188ReO2(tau)]+ 
also succeeded in high yields of 90 – 95 % 
without addition of phosphate buffer solution at 
pH 9 - 10. It was observed, however, that the 
188Re(III)-EDTA precursor complex only formed 
about 50 % of the cyclam complex, despite 
high ligand excess and different reaction con-
ditions (room temperature or 50 - 100 °C, ul-
trasonic, pH 6 - 10). In contrast to the reactions 
with ECD, DMSA or the acyclic amines en and 
tau, which resulted in high yields of the desired 
ligand exchange product, 50 % or more of the 
starting activity was re-oxidised to perrhenate. 
This agrees with observations made by 
Prakash et al. [3], who found that only com-
plexes with acyclic polyamine ligands are 
formed by direct reduction of perrhenate in 
aqueous solutions, while the synthesis of Re-
188 complexes with cyclic polyamines like 
cyclam using the same procedure failed. Obvi-
ously, the formation of the [188ReO2(cyclam)]+ 
complex needs longer time and higher activa-
tion energies than those needed for acyclic 
amine ligands. Thus, the re-oxidation to per-
rhenate is favoured against the ligand ex-
change reaction. The complexes were addi-
tionally characterised by paper electrophoresis 
and anion exchange separation using minicol-
umns filled with Dowex (1x8) ion exchange 
resin (Cl--form). The cationic complexes were 
eluted with water from the anion exchange 
column as radiochemically pure products, 
while the anionic impurities 188Re(III)-EDTA 
and 188ReO4- were retained at the column. 
 
Conclusions 
Rhenium-188(V) oxo- and dioxocomplexes 
with bidentate or tetradentate ligands were 
prepared in high radiochemical yields (with 
exception of [188ReO2(cyclam)]+) by a com-
bined re-oxidation/ligand exchange reaction 
starting from 188Re(III)-EDTA. The formation of 
the precursor complex and the subsequent 
preparation of the desired Re(V)-complexes 
may be performed under mild conditions (room 
temperature, neutral or weak basic solutions, 
low amounts of reducing agent, ligands, and 
auxiliary ligands) and allows consequently the 
labelling of sensitive biomolecules coupled to 
such types of chelates.  
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[2] Park, S. H. et al., J. Labelled Compd. Ra-
diopharm. 47 (2004) 683-697. 
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Hydrophilic Rhenium-188 Complexes for Attaching the Metal to Biomolecules 
6. Complex Design 
E. Schiller, F. Tisato1, H. Spies, H.-J. Pietzsch 
1ICIS-CNR, Padova, Italy 
 
Rhenium-188 complexes with tetradentate/monodentate NS3/P (‘4+1’) coordination represent a flexible system 
which physico-chemical properties can easily be modified. As such modifications have a significant impact on the 
stability of the complexes, guidelines for a rational complex design are needed. 
 
Introduction 
Application of rhenium-188 for therapeutical 
purposes in nuclear medicine requires appro-
priate systems for the stable complexation of 
the nuclide. The ‘4+1’ approach appears to be 
among the promising tools to achieve this goal. 
Besides stability, high hydrophilicity of the rhe-
nium-188 complexes plays an important role, 
aiming at fast renal excretion of radioactive 
metabolites. We synthesised hydrophilic 
ligands for the ‘4+1’ approach and determined 
the in vitro stability of resulting rhenium-188 
complex [1, 2]. These experiments showed a 
strong dependency of the in vitro stability on 
the nature of the ligands, especially on the 
monodentate phosphorous(III) ligand. Based 
on these findings our aim was to map out a 
strategy for a rational ‘4+1’ complex design. 
 
Results and Discussion 
In vitro stability studies showed that the bulki-
ness of phosphorus(III) ligand and the lipo-
philic character of the inner coordination 
sphere were the crucial factors to build up 
stable rhenium ‘4+1’ complexes. Only com-
plexes bearing a bulky phosphorous co-ligand 
(cone angle between 140 ° and 145 °) which is 
able to generate, along with the three thiolate 
sulfurs of the NS3 ligand, a lipophilic area 
around the rhenium are of high in vitro stability. 
Presumably, this lipophilic area prevents the 
Re(III) center from the attack of hydrophilic 
water-derived (by radiolysis) species, such as 
H2O2, or water itself. Additionally, stability can 
be increased by introduction of electron-
withdrawing phosphorous substituents, result-
ing in increased stability of rhenium towards 
oxidation. 
 
Considering the results of the in vitro experi-
ments, monodentate triphenylphosphine lig-
ands seem to be well-suited to create an ap-
propriate lipophilic area around the rhenium. 
An increase of overall hydrophilicity of the rhe-
nium-188 complex can be achieved by pre-
serving the lipophilic core in the inner coordi-
nation sphere and introduction of hydrophilic 
functional groups either at the monodentate 
ligand and/or at the NS3 framework. For the 
latter approach the carboxyl group containing 




Fig. 1. Rational design of rhenium ‘4+1’ complexes  
(X = H O or water-derived species). 2
 
Fig. 1 summarises the arrangement of lipo-
philic and hydrophilic areas. The shown ‘4+1’ 
structure is one possible implementation of the 
requirements discussed above. As can be 
seen in the picture, there are in principal two 
ways of bioconjugating and fine-tuning these 
rhenium-188 ‘4+1’ complexes. First, the car-
boxyl group of the monodentate ligand can be 
used for attaching a target-seeking structure. 
In this case amines bound to the carboxyl 
group of the tetradentate ligand via amide 
bond serve as modulator of physico-chemical 
properties by what the biodistribution pattern 
and excretion can be influenced. The other 
way round, COOH of the NS3 ligand can be 
used for bioconjugation and the carboxyl group 
of the triphenylphosphine derivative for fine-
tuning the physico-chemical properties of the 
complex. The question which approach to use 
maybe depends on the carrier molecule which 
has to be labelled. Further investigations there-
fore are necessary. 
 




[1] Schiller, E. et al., Annual Report 2003, 
FZR-394, p. 45. 
[2] Schiller, E. et al., Annual Report 2004, 
FZR-424, p. 53. 
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Hydrophilic Rhenium-188 Complexes for Attaching the Metal to Biomolecules 
7. Bioconjugation and Radiolabelling 
E. Schiller, J.-U. Künstler, S. Seifert, H.-J. Pietzsch 
 
Aiming at rhenium-188 labelling of target-seeking biomolecules via the so-called ‘4+1’ concept, a water-soluble 
triphenylphosphine derivative was developed as a synthon for the conjugation of carrier molecules, such as pep-
tides and proteins. Exemplary coupling reactions were performed with H-Arg-Tyr-OH and human serum albumin. 
Efforts have been made to label these conjugates with rhenium-188 according to the ‘4+1’ approach.   
 
The identity of 3 was proven by comparison of 
its retention time in HPLC with its non-
radioactive analogue, synthesised in milligram 
amount and characterised by mass spectrome-
try. 
Introduction 
In vitro stability studies of rhenium-188 com-
plexes with ‘4+1’ coordination have shown 
dependencies between sterical and electroni-
cal features of the complex and its in vitro sta-
bility. These findings led to a model enabling a 
rational design of rhenium-188 ‘4+1’ com-
plexes of high in vitro stability [1, 2].  
 
Labelling of human serum albumin (HSA) 
The activated ester 1 was reacted with HSA in 
aqueous solution at pH 8.0 at ratios of 10:1 
and 20:1. The number of conjugated phos-
phine per HSA molecule was determined by 
MALDI-MS and was found to be 7 and 14, 
respectively, meaning a yield of 70 % for each 
coupling reaction.  
Complexes consisting of a carboxyl group 
containing tetradentate NS3 ligand and 4-
diphenylphosphino benzoic acid as monoden-
tate ligand fulfil requirements of the proposed 
model. Methods how to attach these com-
plexes to target-seeking biological structures, 
in particular peptides and proteins, have to be 
found. 
Labelling experiments were done using the 
labile 188Re(III)-EDTA intermediate. As reduc-
tion of perrhenate to this Re(III) species re-
quires acidic conditions we had to neutralise 
this solution before adding the protein. Unfor-
tunately, 25 – 45 % 
 
Results and Discussion 
188The sulfosuccinimidyl activated ester of 4-
diphenylphosphino benzoic acid 1 was synthe-
sised (Fig. 1). This water-soluble reactive com-
pound serves as synthon for the conjugation to 
amino groups of peptides and proteins. The 
dipeptide H-Arg-Tyr-OH and the protein human 
serum albumin were chosen as model com-
pounds for bioconjugation and labelling ex-
periments.  
 
Labelling of H-Arg-Tyr-OH 
The reaction of a 2-fold excess of 1 with H-
Arg-Tyr-OH was completed after 2.5 h at pH 
8.0. Yield: approx. 50 %. The conjugate 2 was 
labelled via the ‘4+1’ approach using a labile 
188Re(III)-EDTA intermediate [3]. Radiochemi-
















Fig. 1. Labelling of H-Arg-Tyr-OH. 
 
ReO4- are formed im-
mediately after neutralisation. Another ap-
proach is the addition of acidic 188Re(III)-EDTA 
solution to a phosphate buffered solution of 
HSA  (3 mg of the 1:20 conjugate). After incu-
bation for 30 minutes at 37 °C we found 
approx. 30 % of the radioactivity bound to the 
protein fraction and 30 % perrhenate.  
 
Summary 
The activated ester 1 serves as suitable com-
pound for 188Re-labelling of peptides in aque-
ous solution. For labelling of proteins reaction 
conditions need to be further optimised. Cru-
cial point is the concentration of phosphine for 
optimal complex formation and adjustment of 
the pH. The latter must be chosen so that on 
one hand the stability of the 188Re(III)-EDTA 
intermediate is high enough for effective label-
ling and on the other hand the integrity of the 
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Formation of Stable Cu(II) Complexes with Hexadentate Bispidine Ligands 
1 1S. Juran, H. Stephan, J. Steinbach, G. Geipel , G. Bernhard
1Institut für Radiochemie 
 
Time-resolved laser-induced fluorescence spectroscopy (TRLFS) has been used to determine the formation con-




Bispidines (bispidine = 3,7-diazabicyclo[3.3.1]-
nonane) show interesting complexation be-
haviour towards transition metals [1]. Consid-
erably high complex stabilities towards Cu(II) 
have been found particularly in the case of 
pyridine-containing ligands [2]. The complex 
stability achieved for copper complexes with 
bispidines, lying in the same range as found 
for macrocyclic compounds, offers the possibil-
ity to apply such complexes for diagnostic and 
therapeutic radiopharmaceutical purposes 
(64/67Cu). Furthermore, the bispidine structure 
opens suitable chemical approaches to intro-
duce biomolecules onto the skeleton. That is 
important in view of the targeting of such com-
plexes.  
Time-resolved laser-induced fluorescence 
spectroscopy (TRLFS) [3] has been applied to 
determine formal stability constants of the 
hexadentate bispidine ligands N2Py4, N2Py4-
OH and the macrocyclic tetraamine cyclam for 


























Fig. 1. Bispidine ligands N2Py4 and N2Py4-OH, and the 
macrocyclic tetraamine cyclam. 
 
Results and Discussion 
Cyclam was purchased from Aldrich. N2Py4 
was prepared according to the known proce-
dure [2]. Reduction of N2Py4 with NaBH4 in 
dioxane gave the mono-ol N2Py4-OH. TRLFS 
experiments were performed as described 
recently [4]. The slope of the “Stern-Volmer-
Plot” gives the formal stability constant [5]. Fig. 
2 displays the fluorescence spectra of N2Py4 in 
methanol and N2Py4-OH in water at different 
copper(II) concentrations. With adding cop-
per(II) to the solution the fluorescence is al-
most completely quenched. This effect is char-
acteristic for high stability constants. The for-
mation constant of a 1:1 complex of N2Py4 with 
Cu(II) was found to be log K11 = 5.94 ± 0.09 in 
methanol. The formation constant of 
N2Py4⊂Cu(II) is more than one order of magni-
tude higher compared to the Cu(II) cyclam 
complex (Log K11 = 4.61 ± 0.21 [6]). Even in 
water the bispidine ligand N2Py4-OH forms a 
































































Fig. 2. Time resolved fluorescence spectra of bispidine 
ligands N2Py4 (methanol, Cu(CF3SO3)2) and N2Py4-OH 
(H O, Cu(NO2 3)2) in dependence on Cu(II) concentration. 
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Complexation of Cu(II) by Glycodendrimers 
1 1 2
 1  (+ 1 eq. of Cu2+) in water
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2  (+ 1 eq. of Cu2+) in water
A. Röhrich, H. Stephan, J. Steinbach, G. Geipel , G. Bernhard , G. Bergamini , V. Balzani2
1 2Institut für Radiochemie, University of Bologna, Italy 
 
Kinetics and stability of Cu(II) complexation by glycodendrimers have been explored. Slow formation of stable 1:1 
complexes was found. 
 
Introduction 
Metalloradiopharmaceuticals of the metallic 
radionuclides 64/67Cu, 99mTc, 186/188Re and 90Y 
are used for diagnostic and therapeutic pur-
poses [1]. Cyclam and its derivatives form very 
stable complexes in particular with transition 
and rare earth metal ions as the radionuclides 
mentioned above [2]. In this nexus, we want to 
develop dendritic ligands having both en-
hanced complex stability and improved bio-
availability. Thus, we built up two glycoden-
drimers possessing a cyclam core modified 
with thiourea-linked sugar residues at the pe-
riphery of the molecule (Fig. 1). D-Glucose and 
2-acetamido-2-deoxy-D-glucose have been 
chosen as sugar moieties. The latter one is 
frequently a part of metabolites of aberrant 















































1 R = OH
2 R = NHAc  
 
Fig. 1. Glycodendrimers 1 and 2. 
 
Results and Discussion 
The glycodendrimers 1 and 2 were prepared 
by glycosylation of the tetraamino-functiona-
lised cyclam core precursor [4] using the O-
acetyl-protected glucosyl isothiocyanates. 
Deacetylation with MeONa in MeOH gave 
compounds 1 and 2. Purification was obtained 
by size exclusion chromatography. Preliminary 
experiments have been performed in order to 
achieve information about the kinetics and 
stability of complex formation of Cu(II) with 
these glycodendrimers. Kinetics of complex 
formation of 1 and 2 with Cu(II) was monitored 
by the change of absorbance at 320 nm (Fig. 
2). The maximum of absorbance was obtained 
at a ratio of 1 between metal to ligand concen-
tration indicating the formation of 1:1 com-
plexes. A slow attainment of complexation 
equilibrium was observed at room tempera-
ture, significantly accelerated at 37 °C. Kinetic 
constants were found to be 185 ± 8 M-1⋅sec-1 
(25 °C), 492 ± 8 M-1⋅sec-1 (37 °C) for 1⊂Cu(II), 
and 340 ± 30 M-1⋅sec-1 (25 °C), 1580 ± 20 M-
1⋅sec-1 (37 °C) for 2⊂Cu(II).  
 
 
Fig. 2. Absorbance of Cu(II) complexes with 1 and 2 as 
function of time and temperature. 
 
 
To estimate the stability of the complexes, 
TRLFS experiments have been performed [5]. 
Formal association constants were determined 
to be log K = 4.51 ± 0.51 (1⊂Cu(II)),11  and log 
K11 = 4.60 ± 0.50 (2⊂Cu(II)). 
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Molecular Structure of the Cluster Anion [TiW11CoO ]8-40
H. Stephan, A. Röllich, Z. Matějka1, G. Reck2 2, W. Kraus
1Institute of Chemical Technology, Prague, 2Bundesanstalt für Materialforschung und –prüfung, Berlin 
 
Hexapotassium dihydrogen monotitanoundecatungstocobaltate(II) tridecahydrate, K H [TiW6 2 11CoO40]·13 H2O, 
crystallizes from aqueous solution in the cubic space group P43m. The [TiW 8-11CoO40]  anion has a Keggin struc-








In recent years, interest in the chemistry of 
metal–oxygen clusters has grown due to their 
applications in areas including catalysis, mate-
rials chemistry and biochemistry. In the latter 
context, polyoxometallates (POMs) show 
unique transport behaviour in living cells, and 
may act as antiviral and antitumoural agents 
[1]. Specifically, the title compound, 
K
Co1
6H2[TiW CoO11 40], reveals promising antitu-
mour activity when applied as starch and lipo-
some hybrid materials [2, 3]. The structural 
characterisation of K6H2[TiW CoO ]·13 H11 40 2O 
is reported here.  
  
Results and Discussion 
K6H2[TiW11CoO40]·13H2O was prepared ac-
cording to the method described by Chen et al. 
[4]. X-ray quality crystals were grown by slow 
evaporation of an aqueous solution at room 
temperature. As shown in Fig. 1, the cluster 
ion has a Keggin structure. It can be viewed as 
a shell of {W11TiO36} encapsulating a central 
tetrahedral {CoO4} group. Alternatively, the 
cluster anion may be described as constructed 
from 12{W0.92Ti0.08O6} octahedra. According to 
the coordination environment of oxygen in the 
anion cluster, the O atoms can be divided into 
four groups. Two kinds of O atoms in the shell 
are connected to the tungsten sites. One bridg-
ing O atom (O1) has a distance of only 
1.819(4) Å to tungsten and the W1-O1-W1 
angle is 148.1(9)°. The second bridging O 
atom (O4) has a distance of 2.034(8) Å to 
tungsten and a smaller angle of 118.6(7)° (W1-
O4-W1). Atom O4 forms hydrogen bonds to 
water molecules outside the shell [O…O = 
2.70(2) Å]. The terminal O3 atoms are con-
nected to only one tungsten atom (O3-W1 = 
1.711(11) Å). The O2 atoms from the {CoO4} 
group connected to W1 have a distance of 
2.231(7) Å. 
In the crystal packing, two symmetry-inde-
pendent potassium atoms, K1 and K2, have 
been found, K2 being positionally disordered 
(Fig. 2). K1 is coordinated by eight cluster O 
atoms, and K2 by four cluster O atoms and 
four water molecules. The structure contains 
13 water molecules per cluster. The coordina-
tion polyhedron formed by K atoms and water 
molecules stabilises the cluster anions in a 
three-dimensional network [5]. 

































Fig. 2. Coordination spheres of the two K atoms. 
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7-Stability Investigation of Nanoparticles Formed by [Ti W PO ]  and Chitosan 2 10 40
T. Meißner, H. Stephan, W. Richter1, H. Zänker1, S. Weiß1
1Institut für Radiochemie 
 
7-Suspensions formed by chitosan and the polyoxotungstate [Ti W2 10PO40]  were investigated by zeta potential 
measurement. The isoelectric point was determined at a [Ti2W10PO40]7- to chitosan molar ratio of 5.5. This relation 
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The modification of antitumorally active poly-
oxometallates (POMs) with organic molecules 
enables the development of metallic drugs 
which have a high biocompatibility, better anti-
tumoral activity and improved stability [1]. Be-
sides the covalent linkage between POM and 
organic units, organic encapsulation of these 
anion clusters is increasingly focused on. In 
this context, promising investigations have 
been done with POMs encapsulated with 
starch and liposomes [2, 3]. We deal with as-
sociates formed by [Ti2W10PO ]7-40  and the bio-
polymer chitosan (Fig. 1). The cell uptake of 
these particles is remarkably enhanced in 
comparison with the free cluster anion 
[Ti
 
Fig. 2. Zeta potential as function of the concentration ratio 
K -5
2W10PO40]7- [4]. In this report, we discuss 
stability studies of the [Ti2W10PO40]-chitosan-
associates (TCA). 
 
Results and Discussion 
[Ti2W10PO40]7- rapidly forms associates with 
chitosan (Mr ~ 10.000 g/mol) in the nanometer 
size range [5]. Our experiments show that size 
and suspension stability depend on the con-
centration and the concentration ratio of the 
two substances. If the molar quotient chitosan : 
[Ti2W10PO40]7- is 1:5, the particles agglomer-
ate. All suspensions which differ from this ratio 
form stable solutions. Interestingly, the 
stoichiometry ratio chitosan : [Ti2W10PO40]7- in 
the isolated associates is also in the range of 
1:5 independently of the educt ratio. Zeta po-
tential measurements (Zetasizer Nano NS) of 
different suspensions have been performed 
(Fig. 2). The isoelectric point was found at a 
[Ti2W10PO40]7- to chitosan molar ratio of 5.5 
indicating the charge neutralisation between 
protonated chitosan and [Ti2W10PO40]7-. Obvi-
ously, there is a correlation between the clus-
ter anion to chitosan molar ratio of the associ-
ates and the isoelectric point we determined. 
7[Ti2W PO10 40] : chitosan (c  = 4⋅10  M). Chitosan
 
To investigate the time-stability behaviour of 
the TCA, 50 mg were placed in vials with 
Sörensen buffer solution (pH 7.4) and then 
kept in an overhead shaker for different times 
(1 - 48 h). After shaking, the mixture was cen-
trifuged and the W- and Ti-concentrations from 
the supernatant were detected by ICP-MS 
which allowed conclusions as to the cluster 
anions that detached from chitosan. After 48 h 
less than 1 % of [Ti2W10PO ]7-40  has been re-
leased from chitosan. 
 
To be published in: Transit. Metal Chem. 
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+ 
Chitosan Mr ~ 10.000 g/mol [Ti2W10PO40]7- Chitosan-[Ti  
 
Fig. 1. Schematic image of [Ti2W10PO40]-chitosan-nanoparticle forming. 
2W PO ]-nanoparticle 10 40
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New Octahedral Rhenium Cluster Compounds Possessing 3,5-Dimethyl-
pyrazole as Apical Ligands 
K. A. Brylev1, Y. V. Mironov1, V. E. Fedorov1 2, H. Spies, H.-J. Pietzsch, H. Stephan, W. Kraus
1Institute of Inorganic Chemistry, Russian Academy of Science, Novosibirsk, Russia,  
2Bundesanstalt für Materialforschung und –prüfung, Berlin 
 
·3,5-Me PzH (1) and [ReTwo new octahedral rhenium cluster complexes, [Re S O(3,5-Me PzH) ]Br Se6 7 2 6 2 2 6 7O(3,5-
Me ·3,5-Me PzH (2), with the organic ligand 3,5-dimethylpyrazole (3,5-MePzH) ]Br2 6 2 2 2PzH), have been synthesised 




The chemistry of the rhenium octahedral clus-
ter compounds with the cluster core {Re6Q8}2+ 
(Q = S, Se) coordinated by organic N- and P-
donor ligands is in a stage of rapid develop-
ment [1, 2]. Such organic-inorganic hybrids 
show interesting electronic, optical, and struc-
tural properties. Furthermore, rhenium clusters 
may play an important role as agents in photon 
activation therapy (PAT) [3]. This relatively 
new treatment paradigm in cancer therapy 
requires a sufficiently high density of metals in 
target regions. This could be achieved by or-
ganic-inorganic rhenium cluster complexes. 
Here we report the preparation and crystal 
structures of two new rhenium octahedral clus-
ter complexes grafted by the organic ligand 
3,5-dimethylpyrazole. 
 
Results and Discussion 
Two new octahedral rhenium cluster com-
plexes, [Re6S7O(3,5-Me2PzH)6]Br2·3,5-Me2PzH 
(1) and [Re6-Se7O(3,5-Me2PzH)6]-Br2·3,5-
Me2PzH (2), with the organic ligand 3,5-dime-
thylpyrazole, have been synthesised by reac-
tion of rhenium chalcobromides Cs3[Re6(µ3-
Q7Br)Br6] (Q = S, Se) with molten dimeth-
ylpyrazole. During the reaction, all six apical 
bromine ligands of the cluster complexes are 
substituted by the organic ligand, which is co-
ordinated through the aromatic nitrogen atom 
N2. Additionally, the inner ligand µ3-Br in the 
cluster core [Re6(µ3-Q7Br)]3+ is substituted by 
oxygen, giving cluster cores [Re6(µ3-Q7O)]2+ 
with mixed chalcogen/oxygen ligands. 
Compounds 1 and 2 have been characterised 
by single crystal X-ray diffraction. The com-
pounds are isostructural. The cluster cations 
[Re6Q7O(3,5-Me2PzH)6]2+ (Q = S, Se) contain 
the Re6 octahedron residing in a Q7O pseu-
docube. There is no disorder in the present 
structures: seven corner positions of the Q7O 
cube are occupied exclusively by S (1) or Se 
(2) atoms and one by an O atom. Due to the 
presence of the O atom in the cluster core 
{Re6Q8}, the Re6 octahedrons in both com-
pounds are slightly irregular. Re-Re distances 
between Re atoms coordinated by the µ3-O 
atom are shorter than those for other Re at-
oms. Each Re atom is coordinated by a 3,5-
Me2PzH. The structure of the sulfur-containing 
cluster cation is shown in Fig. 1. 
 
Fig. 1. Crystal structure of the cluster cation  
[Re6S7O(3,5-Me2PzH)6]2+. 
 
The cluster compounds investigated show 
promising spectroscopic and photophysical 
properties [4]. The great variety of organic 
ligands grafting on the cluster core offers 
abundant opportunities to modify the spectro-
scopic and photophysical properties, and the 
organic shell can make the cluster molecule 
bioavailable. 
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Special Issue: PET in Food Sciences 
J. Pietzsch, J. van den Hoff 
 
Recent progresses in food sciences have led 
to the development of a wide range of excel-
lent analytical methods that enable accurate 
determination of food composition and to study 
food ingredients and contaminants at both the 
micro- and macrostructural level. But this does 
not necessarily tell enough about the nutri-
tional value or the safety of food of interest, 
because only a fraction of biologically active 
compounds present in food can be absorbed 
into the body, and this fraction strongly de-
pends on the type of food and its preparation. 
It is therefore important to know how much of a 
certain substance can be absorbed, what hap-
pens to this substance when it enters the body, 
and, finally, what happens to the body. The 
interest in these questions steadily increases 
due to the fact that the design and develop-
ment of novel foods, genetically modified 
foods, novel food ingredients and additives, 
and new methods of food processing is a rap-
idly evolving field. Furthermore, improved ana-
lytical methods and molecular techniques di-
rect our attention to a rapidly growing number 
of biologically significant substances, including 
numerous functional food ingredients, ‘nu-
triceuticals’, and foodborne toxicants. In this 
context, experimental approaches in vitro offer 
the advantages of providing rapid results, pro-
duced in strictly controlled environments. 
However, they need to be validated increas-
ingly against in vivo studies to make sure that 
they provide a good prediction of what actually 
happens in and with the living organism. The 
latter is a prerequisite to enact new recom-
mendations and regulations, e.g., on novel 
foods and novel processes. In this line, func-
tional imaging by positron emission tomogra-
phy (PET) has been proposed as one tool of 
choice. However, progress in the implementa-
tion of PET in food sciences can only be 
achieved when multidisciplinary PET centers 
closely cooperate with food scientists and 
food-producing companies and, furthermore, 
when industry and regulators are recognizing 
that the use of functional in vivo imaging facili-
tates decision-making whether food compo-
nents are riskful or, on the other hand, main-
tain human health. To instigate a novel discus-
sion forum in this emerging field the 1st Work-
shop on PET in Food Sciences was held in 
Rossendorf in May 2004. As major result a 
Special Issue has been published in Amino 
Acids [1]. This issue contains, beside a review 
article emphasizing new concepts on bio-
markers to assess the effects of dietary expo-
sure, a selection of contributions originally 
presented at this Workshop, under the aus-
pices of the PET Centre at the Research Cen-
ter Rossendorf and the Institute of Food 
Chemistry at the University of Technology 
Dresden [2-11]. In this issue, after a descrip-
tion of the conceptual idea of PET and its mul-
tidisciplinary approach, the needs for new ex-
perimental tools that allow the in vivo assess-
ment of bioavailability, biodistribution, metabo-
lism, and metabolic consequences as well as 
the safety of food contents are specified. Re-
view articles are essentially concerned with 
methodological aspects of PET reviewing cur-
rent developments in PET nuclide production, 
radiochemistry, radiopharmacology, metabolite 
analysis, and quantitative data aquisition and 
analysis. In addition, contributions demonstrat-
ing original experimental applications of PET in 
food sciences have been selected. These arti-
cles deal with various classes of dietary com-
pounds under investigation, including isopep-
tides, and polyphenols. The selected papers 
cover new methods of radiolabelling of isopep-
tides, polyphenols, and lipoproteins. Moreover, 
the use of these novel tracers in dynamic small 
animal PET studies is demonstrated.  
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Radiolabelled Flavonoids and Polyphenols                                                     
IV. Biodistribution of an 18F-Labelled Resveratrol Derivative 
S. Gester, F. Wüst, B. Pawelke, R. Bergmann, J. Pietzsch 
 
18Radiopharmacological evaluation (biodistribution and PET-studies in vivo) of 5-[(E)-2-(4-[ F]fluoro-phenyl)-
ethenyl]-1,3-benzenediol (3,5-dihydroxy-4’-[ 1818F]fluoro-trans-stilbene) [ F]-1 in male Wistar rats is described. 
Compound [18F]-1 shows extensive uptake in the liver and kidneys, respectively. 
 
Introduction 
Recently we have reported the radiosynthesis 
of 18F-labelled resveratrol derivative 5-[(E)-2-
(4-[18F]fluoro-phenyl)ethenyl]-1,3-benzenediol 
[18F]-1 (Fig. 1). Compound [18F]-1 was obtained 
in 9 % radiochemical yield (decay-corrected, 
related to [18F]fluoride) within 120 - 130 min in-
cluding HPLC separation at a specific radio-
activity of up to 90 GBq/µmol. The radiochem-











Fig. 1. Structures of resveratrol and [18F]-1. 
 
In this report we performed the radiopharma-
cological characterisation of 18F-labelled res-
veratrol derivative [18F]-1 by means of biodis-
tribution and small animal PET imaging stud-
ies. 
 
Results and Discussion 
First experiments aimed at the biological be-
haviour of [18F]-1 in vitro and in vivo. Table 1 
shows the distribution of 18F-radioactivity in 
male Wistar rats after single intravenous injec-
tion of [18F]-1. 
 
Table 1. Radioactivity was expressed as percent injected 
dose (% ID) and percent injected dose per gram tissue (% 
ID/g) in different organs. Results are means ± SD (n = 4). 
 
Organ % ID  % ID/g 
 5 min p.i. 60 min p.i.  5 min p.i. 60 min p.i. 
Blood 0.92±0.37 0.31±0.12  0.53±0.09 0.15±0.02 
Brain 0.58±0.20 0.07±0.02  0.33±0.12 0.05±0.01 
Pancreas 0.30±0.07 0.06±0.01  0.52±0.11 0.09±0.01 
Spleen 0.44±0.12 0.32±0.10  0.72±0.15 0.48±0.19 
Adrenals 0.06±0.01 0.02±0.00  0.86±0.23 0.22±0.02 
Kidneys 9.50±0.35 5.59±1.23  4.86±1.09 2.71±0.54 
White fat 0.05±0.01 0.02±0.01  0.16±0.06 0.06±0.01 
Muscle 0.11±0.02 0.03±0.01  0.20±0.01 0.04±0.01 
Heart 0.29±0.03 0.08±0.01  0.37±0.10 0.10±0.02 
Lungs 2.27±0.32 0.49±0.03  1.67±0.37 0.34±0.04 
Liver 25.26±3.29 12.59±1.11  2.18±0.55 1.03±0.24 
Femur 0.19±0.02 0.05±0.01  0.18±0.04 0.05±0.00 
Intestine 4.79±0.84 31.05±3.00  - - 
Urine 28.81±5.13 37.87±5.15  - - 
 
The biodistribution studies showed a very rapid 
clearance of F-radioactivity from the blood. 
The radioactivity concentration at 5 min was 
nearly on the final level. This process was 
accompanied by a rapid uptake both in the 
liver and the kidneys. The fast systemic clear-
ance was similarly accompanied by hepatobil-
iary and renal elimination. The observed 18F-
radioactivity concentration in various tissues 
after intravenous administration of [18F]-1 re-
flects the predominant nonspecific distribution 
presumably according to the high lipophilicity 
of the compound. This observation is consis-
tent with data from the literature. 
Small animal PET imaging studies further con-
firmed this observation. From these studies, 
time-activity curves were obtained for heart, 
liver, kidneys, and intestine (Fig. 2). 
 
 
18Fig. 2. Kinetics of the F-radioactivity calculated by PET 
measurements from ROIs over heart (A), liver (B), kidneys 
(C), and intestine (D). Results are means ± SD (n = 3). 
 
The results from ROI analysis of these organs 
show fast blood clearance, rapid uptake in liver 
and kidneys, and substantial excretion of 18F-
radioactivity into the intestine. These data are 
in agreement with the corresponding results 
obtained from biodistribution experiments. The 
tissue localisation of 18F-radioactivity reflects 
both, intact [18F]-1 and its 18F-labelled metabo-
lites. The very fast excretion of 18F-radioactivity 
into bile/intestine and urine found is consistent 
with findings on rapid formation of hydrophilic 
metabolites from resveratrol and analogues in 
the literature. 
 




[1] Gester, S. et al., Annual Report 2004, FZR-
424, p. 67. 
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Operation of the Rossendorf PET Cyclotron "CYCLONE 18/9" in 2005 

























C-11 [F-18]F2 [F-18]F- O-15 N-13
The radionuclides produced in routine opera-
tion in 2005 were F-18 and C-11, available as 
[18 -F]F , [18F]F2 and [11C]CO2. The improved 
version of the Rossendorf solid target system 
[1] was used for the routine production of 86Y. 
Table 1 gives an overview of the 2005 ra-
dionuclide production. 
Due to an increasing demand of C-11 based 
radiopharmaceuticals and radiotracers the 
daily operating time of the CYCLONE 18/9 
increased by 15 % with regard to the maximum 
value of 2004 and varied now between three 
and six hours. 
 























Table 1. Radionuclide production in 2005 
 
Radionuclide production  




[18 -F]F 307 11145 
[18F]F2 *) 326 1282 
11C 278 12101 
86Y 19 24.6  
  *) including pre-irradiations  Fig. 2a, b. Total amount of activity produced. 
  
Fig. 1 shows the number of target irradiations 
and Fig. 2 the total amount of activity produced 
over the last seven years (1999 to 2005). 
Maintenance and service 
- Stripper foils 
The serious problems with the carbon stripper 
foils occurred in 2004 [2] were overcome. We 
























C-11 [F-18]F2 [F-18]F- O-15 N-13 2 
areal density (Minteq International Inc./USA). 
These foils are more resistant against possible 
RF currents and neutral beam effects inside 
the vacuum chamber. 
 
- Annual check of the cyclotron 
The annual check of the CYCLONE 18/9 facil-
ity by the TÜV Sachsen organisation (TÜV = 
Association for Technical Inspection) under     
§ 66 (2) of the Radiation Protection Regulation 
was carried out in the second half of Septem-
ber 2005. There were no objections to the 
further operation of the cyclotron.  
 




















Status of the CYCLONE 18/9 
Though the number of beam hours (ion beam 
on the targets) has increased over the last 
years (see Fig. 3) and we are still able to fulfil 
all demands until now it is worth to mention 
that many of the CYCLONE 18/9 subsystems 
are of ‘state of the art’ of the beginning of the 
1990
 
 th. The same is true for our 500 m in 
length Radionuclide transport system (RATS) 
between the cyclotron building and the radio-
Fig. 1a, b. Number of irradiations of radionuclides 
produced. 
41 
   
chemistry building including the control sys-
tems of the cyclotron and RATS. 
- Exposure to radiation of the cyclotron staff 
The cyclotron staff belongs to category A of 
occupational exposed persons. The average 
exposure to radiation of the cyclotron staff over 
the years of cyclotron operation is shown in 
Table 3.  
 


















Table 3. Average exposure to radiation of the  
cyclotron staff 
 
Year Exposure [mSv] 
1997 1.8 
1998 2.9 
1999 3.5  
 2000 6.2 
Fig. 3. Beam hours over the years (p = protons,  2001 4.6 D = deuterons) 
2002 1.7  
2003 2.6 Our cyclotron is the second one of the IBA 
CYCLONE 18/9 series and has some disad-
vantages (dees fixed on the top, targets out-
side the yoke) that have been overcome with 
the following ones. Especially the old PLC 







[1] Preusche, St. et al., Annual Report 2004,  
 FZR-424, p. 73. 
Radiation protection [2] Preusche, St. et al., Annual Report 2004,  
FZR-424, p. 71. - Emission of radionuclides with the exhaust air 
 The emission of radionuclides with the exhaust 
air is routinely monitored. As shown in Table 2, 
it is well below the limit of 2.0E11 Bq.  
 
Table 2. Emission of radionuclides with the exhaust air in 
2005 as a result of cyclotron operation  
 
Radionuclide Emission [Bq/a] 
Ar  41 1.9E10 
F  18 4.6E09 
Sum 2.3E10 
Percentage of the 
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The Institute sustains a number of valuable collaborations with other research institutions and is en-
gaged in joint projects funded by federal and trans-national authorities and research initiatives as well 
as by the industry.  
 
Naturally, the Technical University of Dresden continues to be an important partner in our cooperative 
relations. Cooperations exist with various groups in the Department of Chemistry and the Faculty of 
Medicine. Common objects of radiopharmacological and medical research link the Institute with the 
University Hospital in Dresden, above all with its Department of Nuclear Medicine (Prof. Kotzerke) 
which contributes to the staff of the jointly operated PET Centre Rossendorf. Application of the posi-
tron emission tomography technique has been successfully extended to new questions in collabora-
tion with the Institute of Food Chemistry (Prof. Henle). Fruitful collaborations on the development of 
novel PET radiotracers have been established with the Institute of Organic Chemistry (Prof. Metz) and 
the Institute of Biochemistry (Prof. van Peè). Bioinorganic research activities are closely linked with the 
Department of Coordination Chemistry (Prof. Gloe).  
 
On the national and international level, there exist a number of collaborations.  
In 2005, the new interdisciplinary research centre "OncoRay" for radiation research in oncology has 
been established in Dresden. OncoRay's vision is to improve the treatment of cancer by means of 
biologically individualised, technically optimised radiotherapy. Our institute is one of the main collabo-
rators of OncoRay, the focus of the collaboration currently being on small animal investigations with 
PET and MRI. 
 
The identification of common objects in PET radiopharmacy has led to collaborative research with the 
Institute of Interdisciplinary Isotope Research at the University of Leipzig (Prof. Steinbach). Both insti-
tutes constitute an alliance of research in radiopharmaceutical sciences. 
  
Cooperation in PET tracer chemistry and radiopharmacology has been established with the Turku 
Medical PET Center (Prof. Solin), Washington University, School of Medicine in St. Louis (Prof. Welch 
and Prof. Anderson), Harvard School of Medicine in Boston (Dr. Neumeyer), Northeastern University 
Boston (Prof. Hanson), University of Illinois in Champaign-Urbana (Prof. Katzenellenbogen) and the 
Instituto Tecnológico e Nuclear in Sacavèm (Dr. Santos).  
 
Cooperation in the field of peptide chemistry and receptor research exists with the University of Leip-
zig (Prof. Beck-Sickinger) and the Free University of Brussels (Prof. Tourwe).  
 
Investigations on the field of metabolic research (lipoprotein metabolism, atherogenesis and inflamma-
tion) are closely performed in collaboration with the Medical Clinic and Outpatient Department III, 
University Hospital Dresden (Prof. Julius; Dr. Kopprasch). 
 
Strong collaboration exists in the field of development and characterisation of new metalloradiopharm-
ceuticals with the University of Ferrara (Prof. Duatti), Research Centre ICIS CNR Padova (Dr. Tisato), 
Institute of Nuclear Chemistry and Technology Warsaw (Prof. Narbutt), Russian Academy of Sciences, 
Institute of Inorganic Chemistry Novosibirsk (Prof. Fedorov), University of Heidelberg (Prof. Comba). 
 
Structural modelling and structure-property correlations of new radiometal complexes are performed 
together with groups of the University of Heidelberg (Prof. Comba) and the University of Kitakyushu 
(Prof. Yoshizuka).  
 
Very effective cooperation exists with the Federal Material Research Institute in Berlin (Dr. Emmerling, 
Mr. Kraus), whose staff members carried out X-ray crystal structure analysis of new technetium and 
rhenium complexes.  
 
In the field of supramolecular chemistry, successful cooperation exists with the University of Bonn 
(Prof. Vögtle), Free University of Berlin (Prof. Schalley), University of Münster (Prof. De Cola), Univer-
sity of Duisburg-Essen (Prof. Klärner), University of Bologna (Prof. Balzani), University of Fribourg 




PUBLIC FUNDED PROJECTS 
 
The Institute is part of the Research Center Rossendorf, which is financed by the Federal Republic of 
Germany and the Free State of Saxony on a fifty-fifty basis.  
 
 
The Institute participated in the following networks supported by Commission of the European Com-
munities:  
 
Radiotracers for in vivo assessment of biological function  
COST B12  
in collaboration with Sweden, Italy and Switzerland.  
02/1999 – 04/2005  
 
Since 2004, the Institute is engaged in the SIXTH FRAMEWORK PROGRAMME PRIORITY 1 FP6-
2002 LIFESCIHEALTH, in the project BioCare, Molecular Imaging for Biologically Optimized Cancer 
Therapy, Contract no.: 505785. The Institute contributes to the work packages: WP 3 - Molecular im-
aging of radiation therapy induced alteration of tumour cell proliferation and functional receptor ex-
pression, WP 4 - Aptamer based PET and SPECT tracers for molecular tumour imaging, together with 
partners from the Technical University of Dresden, Universitair Ziekenhuis Gasthuisberg, Université 
Catholique de Louvain, and University of Hamburg.  
04/2004-10/2008  
 
The Institute further contributes to POL-RAD-PHARM (MARIE CURIE TRANSFER OF KNOWLEDGE 
FELLOWSHIP). Project full title: Chemical Studies for Design and Production of New Radiopharma-
ceuticals. The project aims at commencing and intensifying research in radiopharmaceutical chemistry 
– a new discipline for the host institution. For this purpose the host institution, located in Poland, has 
established partnership with other seven European laboratories.  
The research part of the project includes:  
(1) learning and/or mastering methods for obtaining novel potential radiopharmaceuticals labelled with 
99mTc (diagnostic) and with 188Re (therapeutic);  
(2) developing a method for labelling biomolecules with 211At by formation of stable heteroleptic com-
plexes between astatide (At-) and chelates of soft metal cations;  
(3) developing methods for obtaining selected radionuclides of potential use in manufacturing radio-
pharmaceuticals, including metallic PET nuclides and alpha-emitters;  





The Institute participates in the following networks supported by Commission of the European Com-
munities (1) and International Atomic Energy Agency (2): 
 
(1) Toward Bio-Inspired Photoadressable Supramolecular Systems. Synthesis, Light-emission, Dy-
namics, Biomedical Application (COST D31) 
in collaboration with Italy, Switzerland, Portugal and Czech Republic. 
04/2005-02/2009 
  
99m(2) IAEA Co-ordinated Research Programme on “Development of Tc based Small Bio Molecules 
Using Novel 99mTc Cores”  













On the national level, two research projects concerning tracer design, biochemistry and PET radio-
chemistry were supported by the Deutsche Forschungsgemeinschaft (DFG):  
 
Molecular encapsulated 188Re complexes: development of robust and tunable radioactive rhenium 
complexes on the basis of novel chelators derived from dimercaptosuccinic acid (DMSA).  
PI 255/5-2 (H.-J. Pietzsch) 04/2005 – 03/2007  
 
F-18-labelled corticosteroides as ligands for imaging brain glucocorticoid-receptors by means of PET. 
WU 340/1-2 (F. Wüst) 11/2004 – 10/2006  
 
 
The Sächsisches Staatsministerium für Wissenschaft und Kunst provided support for the following 
project:  
 
MeDDrive 2002  
01/2004 – 12/2006  
 
 
The Sächsisches Staatsministerium für Wirtschaft und Arbeit provided support for the following pro-
jects: 
 
Radioimmunodiagnostics of inflammation  
05/2004 - 06/2007 
 
Radioactively labelled human serum albumin microspheres for tumour therapy 
 03/2005 – 06/2007 
 
Analytics of MAG (GWT) 3 
 10/2005 – 08/2007  
 
 
The Bundesministerium für Bildung und Forschung supported cooperation with  
 
Czech Republic: Polyoxometallo compounds  
WTZ, 08/2002 – 07/2005  
 
Russia: Polynuclear metallo drugs  
WTZ, 07/2003 – 06/2006  
 
 
The Bundesministerium für Wirtschaft und Arbeit supported research projects on:  
 
Preparation of 86Y  
08/2003 - 01/2005  
 
 
Several laboratory visits were supported by the “Deutscher Akademischer Austauschdienst” (DAAD).  
VIGONI-Project with Padova (Italy):  
Labelling Dithiol Ligands with a TcN-Synthon  
01/2005 – 12/2005  
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FINANCIAL SUPPORT BY THE INDUSTRY  
 
The following projects were supported by cooperations with the industry:  
 
ABX advanced biomedical compounds GmbH Dresden  
 GSK/5-HT6 tracer and ligand characterisation 
 04/2005 – 12/2006 
 
ABX advanced biomedical compounds GmbH Dresden  
PET surrogate parameters  
10/2003 - 06/2006  
 
Apogepha Arzneimittel GmbH  
Cooperation in pharmakokinetics and metabolism of propiverin  
07/2003 – 04/2005  
 
A.R.T. Hersching  
Cooperation in movement tracking for PET  
09/2002 – 12/2006  
 
Bayer AG Leverkusen  
Cooperation in drug development  
05/2002 – 09/2005  
 
Bruker BioSpin MRI GmbH  
MPI/PET-Coupling  
11/2003 – 12/2006  
 
Nihon-Medi-Physics (Japan/USA)  
Development and evaluation of technetium-99m-labelled fatty acids  
01/2003 – 12/2005  
 
ROTOP Pharmaka GmbH  
Agent syntheses  
06/2004 – 12/2006  
 
Schering AG Berlin  
Pharmaceutical research  
07/1996 - 12/2006  
 
Schering AG Berlin  
Metal chelates  
05/2003 - 12/2006  
 
Schering AG Berlin  
 Dialysis 
 09/2005 – 09/2006 
 
AEA Technology, QSA GmbH, Braunschweig 
 Preparation of 86Y 















Dr. J.-U. Künstler 
Medizinische Universität Innsbruck, Nuklearmedizin, Austria 
06.-13.11.2005 
 
Dr. M. Walther 






Dr. E. Gniazdowska 
Institute of Nuclear Chemistry, Warsaw, Poland 
17.01.–13.03.2005 
 
Dr. M. Urbanová 












Institute of Chemical Technology, Prague, Czech Republic 
04.–08.05.2005 
 
Dr. V. Setnička 
Institute of Chemical Technology, Prague, Czech Republic 
04.–08.05.2005 
 
Dr. M. Urbanová 
Institute of Chemical Technology, Prague, Czech Republic 
04.–08.05.2005 
 
Prof. M. T. Gandolfi 




University of Bologna, Italy 
05.–08.05.2005 
 
Dr. E. Gniazdowska 














nd2  SUPRAPHONE Meeting  






Summer term 2005 
 
H.-J. Pietzsch 
One term course on Metals in Biosystems (Introduction into Bioinorganic Chemistry) 
 
J. Pietzsch 
Lipoproteins and Atherogenesis 
 
 
Winter term 2005 
 
F. Wüst 
One term course on Radiopharmaceutical Chemistry 
 
J. Oswald 






Coordinator of Working Group 0011/04 "Toward Bio-Inspired Photoadressable Supramolecular Sys-
tems. Synthesis, Light-emission, Dynamics, Biomedical Applications" within the COST Action D31 




























































TALKS OF VISITORS 
 
Dr. M. Urbanová, Institute of Chemical Technology Prague 
Circular dichroism spectroscopy of biomolecules 
21.02.2005 
 
Dr. N. Budisa, Max-Planck-Institut für Biochemie, Martinsried 
Expanding the genetic code for expression of novel protein derivatives and conjugates 
08.06.2005 
 
M. Eiblmaier, Washington University, School of Medicine 




Prof. O. Solin, Turku PET Centre 
18High specific radioactivity F-tracers for positron emission tomography 
16.09.2005 
 
Prof. Dr. K. Takeshita, Tokyo Institute of Technology 
Extraction separation of Am(III) and Eu(III) with TPEN (N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylene-
diamine) and its derivatives 
29.09.2005 
 
Prof. Dr. F.-G. Klärner, Institut für Organische Chemie der Universität Duisburg-Essen 
Neues aus der Chemie der molekularen Pinzetten und Klammern 
11.10.2005 
 
Prof. Dr. K. Lützenkirchen, Institute for Transuranium Elements Karlsruhe, Joint Research Center – 
European Commission 

































INTERNAL SEMINARS  
 
K. Strobel 








EU-Projekt „BIOCARE“ (WP4): Entwicklung von Aptameren zur Tumordarstellung 
05.04.2005 
 
R. Bergmann/C. Pötzsch 




EU-Projekt: „BIOCARE“ (WP3): Etablierte und neue PET-Tracer in der Strahlentherapie – Evaluierung 
mittels MicroPET, Autoradiographie und „Funktioneller“ Histologie am Tiermodell. 
02.05.2005 
 
St. Preusche/F. Wüst 
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Görner, H. Krauß, E. Rode, K.* 
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(who left during the period covered by the report) 
 
 Forker, S. Administrative Staff: 
   
Dr. Grote, M.* Dr. Pawelke, B.* Scientific Staff: 
   
Roß, H.  Technical Staff: 
 
 
* term contract ** on maternity leave *** guest scientist  
 
 
 
 
 71
